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 Zusammenfassung 
 
Telomerverkürzungen begrenzen die regenerative Kapazität von primären menschlichen 
Zellen in vitro durch die Induktion von zellulärer Seneszenz. Das Stadium der Seneszenz tritt 
auf, wenn Telomere eine kritisch kurz Länge erreichen. Seneszenz ist durch einen 
permanenten Wachstumsarrest gekennzeichnet. In dieser Arbeit haben wir Leberregeneration 
in Telomerase defizienten Mäusen untersucht, um zu erfassen, ob das in vitro Modell der 
zellulären Seneszenz auch für die durch Telomerverkürzung begrenzte Organregeneration in 
vivo zutrifft. Unsere Arbeiten zeigen, dass Telomerverkürzungen auf zellulärer Ebene in 
einem Organ heterogen auftreten und dass kritisch kurze Telomere eine Subpopulation von 
Zellen kennzeichnen, die im Rahmen der Regeneration vom Zellzykluseintritt gehemmt sind. 
Diese Subpopulation von nicht-proliferierenden Zellen zeigt Senszenz-assoziierte-β-
Galaktosidase-Aktivität - ein biochemischer Marker zellulärer Seneszenz. 
Genexpressionsanalysen zeigten eine Hochregulation von Zellzyklusinhibitoren, die unter 
anderem auch Targetgene des p53-Gens enthielten, welches als Markergen von Seneszenz 
gilt.  Unsere Studien zur Induktion und Aufrechterhaltung zellulärer Seneszenz in primären 
menschlichen Fibrobalsten und Mausleber haben eine Zellzyklusabhängigkeit des Seneszenz-
Signalwege aufgezeigt. Die Seneszenz-Signalwege sind schwach aktiv in ruhenden Zellen, 
wohingegen in Zellen, die zum Zellzykluseintritt angeregt werden, eine volle Aktivierung der 
Seneszenz-Signalwege auftritt. Die Amplifizierung der Szeneszenz-Signalwege durch 
Mitogenstimulation ist zum Teil durch den MEK/MAPK-Signalweg vermittelt. Unsere 
Analyse humaner Leberproben zeigte, dass Seneszenz-assoziierte-β-Galaktosidase-Aktivität 
in 84% von Leberzirrhoseproben auftritt aber nicht in nicht-zirrhotischen 
Kontrolllebergewebe. Diese Daten indizieren, dass die Telomerhypothese zellulärer 
Seneszenz für die Entstehung von menschlicher Leberzirrhose zutrifft, ein Krankheitsstadium, 
dass durch den Verlust hepatozellulärer Regenerationsfähigkeit gekennzeichnet ist. Unsere 
Arbeiten indizieren, dass zelluläre Seneszenz in vivo auftritt und funktionellen Einfluss auf 
Organregeneration hat. Im Mausmodell zeigen unsere Arbeiten, dass die gehemmte 
Organregeneration in Organen mit kurzen Telomeren durch zusätzliche Zellteilungsrunden 
von Zellen mit ausreichender Telomerlänge kompensiert werden kann. Diese Ergebnisse 
indizieren, dass das Ergebnis chronischer Erkrankungen und chonisch regnerativer Prozesse 
während der Alterung  von der Ballance zwischen regnerierenden und nicht-regenerierenden 
Zell abhängt, eine Ballance, die durch die Telomerlänge auf zellulärer Ebene bestimmt wird.
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Abstract 
 
Telomere shortening limits the regenerative capacity of primary cells in vitro by 
inducing cellular senescence characterized by a permanent growth arrest of cells with 
critically short telomeres.  To test if this in vitro model of cellular senescence applies to 
impaired organ regeneration induced by telomere shortening in vivo, we monitored liver 
regeneration after partial hepatectomy in telomerase deficient mice. Our study shows 
that telomere shortening is heterogeneous at the cellular level and inhibits a sub-
population of cells with critically short telomeres from entering the cell cycle. This sub-
population of cells with impaired proliferative capacity shows senescence associated β-
galactosidase activity a marker of senescence. Expression profiling of the effected organ 
shows upregulation of cell cycle inhibitors including downstream tragets of p53 -  a 
marker gene of replicative senescence. Our studies on induction and maintenance of 
replicative senescence in primary human cells and in mouse liver show that the 
replicative senescence pathway is cell cycle dependent. It operates at a low level in cells 
with shortened telomeres but becomes fully activated when cells are stimulated to enter 
the cell cycle.  The amplification of replicative senescence signalling by mitogen-
stimulation is in part mediated through MEK/MAPK-pathway. Our analysis on human 
liver samples reveals that senescence-associated ß-galactosidase staining is present in 
84% of cirrhosis samples but not in non-cirrhotic livers indicating that the telomere 
hypothesis applies to cirrhosis formation, which is charaterized by cessation of heptocyte 
regeneeration. This study provides experimental evidence for the existence of an in vivo 
process of cellular senescence induced by critical telomere shortening that has functional 
impact on organ regeneration. We show in the mouse model that impaired regeneration 
of an organ with shortened telomeres can be accomplished by cells with sufficient 
telomere reserves that are capable of additional rounds of cell division. These findings 
indicate that the outcome of chronic diseases and tissue regeneration during aging 
depends on the balance of proliferative to non-proliferative cells determined by telomere 
length at cellular level. 
 
Stichworte: Zelluläre Seneszenz, Organ Regeneration, Telomerverkürzun 
Keywords: Cellular senescence, Organ regeneration, Telomere shortening 
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  Introduction 
1. Introduction: 
1.1 Structure and Function of Telomeres 
Telomeres are specialized nucleo-protein structures that form the physical ends of 
linear eukaryotic chromosomes (1, 2). The name ‘telomere’ (telos=end; meros=part) and the 
observation of the specialized genetic structures at the ends of chromosomes dates back to 
1938. Using cytogenetic approaches, Muller and McClintock independently observed that 
natural chromosome ends, unlike random DNA breaks, had special properties that protected 
them from end-to-end fusions.  Due to extensive research efforts for the past few years, now it 
is known that highly conserved telomere structures at the ends of linear chromosomes consist 
of tandem repeat DNA sequences and associated proteins (1, 2). Mammalian telomeric DNA 
is composed of G-rich tandem repeats of the sequence (TTAGGG)n, which in humans 
extends 10-15 kilo bases (Kb) where as in inbred mouse strains it is approximately 40 – 60 Kb 
(3, 4, 5). The sequence of human telomeres was identified by Moyzis in 1988 (6). 
Cytologically, telomeres in a variety of plants and animals are heterochromatic, implying a 
high degree of DNA folding (7). The bulk of telomeric DNA is double stranded, but the 
extreme terminus of telomeric DNA consists of a 3’ overhang of approximately 200 bases. 
The G-strand overhang is the substrate to which telomeric repeats are added by telomerase (8, 
9).  
 
Recent discoveries suggest that telomeres exist in at least two different states or 
architectures: an ‘open’ and a ‘closed’ complex. The ‘closed’ complex is thought to represent 
the state that caps and protects chromosome ends. In mammals and some other species a 
lasso-like structure, called the t-loop, has been observed (10, 11). In the t-loop model for this 
higher order ‘closed’ complex structure, the 3’- single-stranded overhang folds back into the 
double-stranded telomeric tracts, providing one solution to the end-protection problem. The 
‘open’ complex is probably not only required for the telomerase to access the end of the 
telomeric DNA for telomere elongation (see below), but most likely the opening of the 
tertiary telomere structure is also necessary to allow telomeric DNA replication during S-
phase. Therefore it is likely that different telomere states – open or closed - are cell cycle-
dependent. 
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  Introduction 
 
Telomere 
Centromere 
Figure 1.1.1 Structure of metaphase chromosomes. (5) (Liu Y, Kha H, Ungrin M, Robinson 
MO, Harrington L. Preferential maintanance of critically short telomeres in mammalian cells 
heterozygous for mTERT. Proc. Nat .acad. sci., 2002, 99, 3597-3602). 
 
Maintenance of functional telomeres at chromosome ends is required for the 
prolonged survival of most organisms with linear chromosomes. The primary function of 
telomeres is to cap and protect the chromosomal ends (12, 13). Telomeres are also involved in 
several essential biological functions. They protect chromosomes from recombination, end-to-
end fusion, and recognition as damaged DNA (12-16), provide a means for complete 
replication of chromosomes, contribute to the functional organization of chromosomes within 
the nucleus (17), participate in the regulation of gene expression (18), and serve as a 
molecular clock that controls the replicative capacity of human cells and their entry into 
senescence (see below, 19-21).  
 
1.2 Telomere binding proteins and their function 
The terminal regions of the telomeric double-stranded DNA repeats in humans (and 
other species) are thought not to be packaged into nucleosomes (22), but together with the 
single-stranded overhang serve the crucial function of providing binding sites for sequence-
specific DNA-binding proteins that bind to and stabilize telomeres (23-25) and possibly 
involve in telomere mediated responses (12-16, 26). Some of these proteins are necessary for 
the formation of higher order telomere structures, such as T loops, D loops (10, 11) or G-
quartets (27), which appear to be essential for telomere capping function.               
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Figure 1.2.1 Classical versus new view of telomere structure (11) (C.W.Greider, Telomeres 
do D-loop, T-loop. Cell, 97, 419-422). 
 
These DNA-binding proteins in turn recruit other proteins to the telomere, forming a 
multi-protein telomeric cap (14, 28). The most striking feature of these telomeric proteins is 
that they bind to double-stranded DNA via a structurally conserved DNA-binding domain of 
the Myb/homeodomain type (29). Myb/homeo-domains belong to the common helix–turn–
helix (HTH) family of DNA-recognition motifs found in many transcription regulators.  
 
Two Myb-related telomere repeat binding proteins, TRF1 and TRF2, have been 
characterized and play important, but apparently distinct, roles in telomere length homeostasis 
(23, 24, 29). TRF1 and TRF2 and their associated proteins have the primary responsibility of 
stabilizing the complex and forming the t-loop (10, 11).  Some degree of stabilization is 
intrinsic to the telomere overhang due to the G-rich nature of the TTAGGG repeats that form 
quadruplex structures.  TRF1 is important in intra-telomeric coiling and it acts as a negative 
regulator of telomere length and function (23).  TRF2 also binds along the length of the 
telomere but appears to be particularly abundant at the base of the t-loop and is important for 
its stabilization and formation (24).  These duplex telomere DNA binding proteins also have 
their own associated proteins (13, 14, 28).   
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One such protein is Rap1p, which is integrated into the t-loop complex and interacts 
with TRF2, but its specific role in humans is unknown (25).  Tankyrase has the ability to 
inhibit TRF1, thereby releasing it from the t-complex and allowing telomerase and other 
enzymes to bind (30).  TIN2 promotes TRF1 function and causes it to bind to telomeres (31).  
The single-stranded G-rich overhang binds Pot1 which is the terminal transducer of TRF1 
telomere length control (32). 
 
Figure 1.2.2 T-loop, D-loop structure of mammalian telomere. (33) (Shay, JW: At the end of 
the millennium, a view of the end. Nat Genet 1999, 23:382 383.) 
 
 
The DNA damage response complex RAD50/MRE11/NBS1 also co-operates with 
TRF2 (34).  The MRE11 complex functions conventionally in homologous recombination to 
repair DNA double strand breaks (35).  At the telomere, however, it is thought to stabilize the 
T-loop where the single stranded tail invades the duplex telomere.  Based on its function in 
vitro, the role of NBS1 during the S phase may be to unwind the T-loop via a helicase (34). 
Ku70 and Ku86, together with DNA-PKcs, form an enzyme called DNA dependent protein 
kinase (DNA-PK), which is involved in DNA double strand break (DSB) repair by NHEJ and 
in V(D)J recombination. Ku proteins also interact with TTAGGG repeats and with telomeric 
proteins TRF1 and TRF2 (36). 
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Figure 1.2.3 The nucleo-protein complex, telomeres with its associated binding proteins (37) 
(Rhodes D, Fairall L, Simonsson T, Court R, Chapman L. Telomere architecture. Embo Rep. 
2002, 3, 1139-45). 
 
It appears that in addition to these known telomere binding proteins there might be 
several other proteins which involve in telomere stabilization and integrity and telomere 
mediated responses. Identification and functional analysis of these proteins lead to a better 
understanding of the structure and integrity of the telomeres. A selective disruption of the 
telomere integrity might be a new therapeutic approach to  inhibit cancer cell growth, whereas 
stabilization of telomeres could be useful to prevent chromosomal instability and cancer 
initiation.  
 
1.3 DNA end replication problem 
Replication of linear chromosomes presents a special problem and Watson and 
Olovnikov independently hypothesized that linear DNA progressively looses some of its 
sequence at the very ends each time a cell divides (38). Their theoretical hypothesis was latter 
proven by showing that DNA polymerase can only synthesize a new strand of DNA as it 
moves along the template strand in the 3' Æ 5' direction. This occurs on the 3' Æ 5' strand 
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(leading strand) of a chromosome as the DNA polymerase can move un-interruptedly from an 
origin of replication until it meets another bubble of replication or the end of the chromosome. 
In contrast, DNA-synthesis using the 5' Æ 3' strand (lagging strand) as the template is 
discontinuous and requires small RNA-primers for initiation of DNA-replication. When the 
replication fork opens sufficiently, DNA polymerase binds to the RNA-primer  and begins to 
synthesize a section of complementary strand - called an Okazaki fragment - proceeding in 
the opposite direction of the movement of the replication fork. This continues until close to 
the end of the chromosome. Later, DNA ligase, ligates the Okazaki fragments together. 
However, the molecular requirements of the process are such that 5' end of each newly-
synthesized strand can not be replicated completely. Thus each of the daughter chromosomes 
will have a shortened telomere (the end replication problem).   It is estimated that human 
telomeres lose about 50-100 base pairs from their telomeric DNA after each round of 
replication (19-21). This represents about  10-15 TTAGGG repeats.  
 
Figure 1.3.1 The end replication problem (The cell cycle: DNA replication, mitosis and 
cancer, Chapter 17, Addison wisely Longman) 
 
 
1.4 Telomerase 
The DNA polymerase’s inability to complete DNA replication until the extreme ends 
of the telomeres was compensated for by the reverse transcriptase enzyme telomerase, which 
synthesizes telomere repeat units de novo by adding one nucleotide at a time, to single-
stranded chromosome ends (39). Telomerase enzyme was discovered in the unicellular 
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protozoan Tetrahymena thermophila (40). The telomerase holoenzyme consists of two 
essential components: telomerase RNA component (TERC) (41), which serves as a template 
for the synthesis of telomere sequence and the telomerase reverse transcriptase (TERT), 
which is the catalytic component of the enzyme (42). When a chromosome is replicated, the 3' 
hanging parental fragment containing the G-rich sequence GGGTTA  is recognized by the 
telomerase complex.  Using its own RNA as a complementary primer, the telomerase mimics 
reverse transcriptases and elongates the hanging DNA fragment in the 5' to 3' direction. 
 Replication of the lagging strand can now be completed using the telomeric extensions as a 
template for synthesis using DNA polymerase.  
 
 
Figure 1.4.1 Structure of telomerase holoenzyme and the mechanism of action at the 
telomeric ends. (43) (Blackburn EH, The telomere and telomerase: nucleic acid-protein 
complexes acting in a telomere homeostasis system. A review. Biochemistry (Mosc). 1997, 
62, 1196-201). 
 
 
In cells with active telomerase, the telomere-telomerase complex comprises a dynamic 
system in which telomeric DNA length is continually being built up and shortened in a 
regulated way that maintains telomere length homeostasis and retains telomere functionality 
(43). The action of telomerase is regulated by sequence-specific DNA binding proteins that 
bind the telomeric DNA repeats. The human holoenzyme requires the proteins p23 and hsp90 
to assemble the telomerase components in vivo (44). The telomerase gene was recently 
mapped to 5p15.33 as one of the most distal genes on chromosome 5p (45).  This has raised 
questions about whether its proximity to the telomere might result in it being regulated by 
‘telomere position effect’ mechanisms. Telomere position effect (TPE) results in the 
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reversible silencing of genes near telomeres by a mechanism that depends both on telomere 
length and on the distance to the gene (18, 46). Because telomeres in most human cells 
shorten with age, TPE would provide a mechanism to incrementally alter phenotype with 
increasing cellular age. The existence of TPE in mammalian cells raises the possibility that 
some presenescent changes could be "programmed" by the progressive shortening of 
telomeres with ongoing cell division, leading to altered patterns of gene expression that might 
affect both cell and organ function (18, 46). 
 
In humans, telomerase expression is tightly regulated. It is active only during 
embryogenesis, whereas its postnatal activity is suppressed in most somatic tissues but 
remains active in a subset of cells, such as germ cells (47), stem cells, progenitor cells (48), 
and activated lymphocytes (49-51). TERC is ubiquitiously expressed, where as TERT 
expression is suppressed and acts as a rate limiting factor in most somatic cells and tissues 
leading to inevitable loss of telomere repeats at a rate of 50-100bp (52, 53). Postnatal 
suppression of telomerase expression in most somatic tissues is thought to represent a potent 
anti-tumor barrier not allowing the immortal growth of transformed cells (54). The molecular 
mechanism for postnatal inactivation of telomerase in humans is not well known and remains 
to be elucidated. Several lines of evidence suggest that the existence of repressors rather than 
the absence of activators might control the tight regulation of TERT expression in humans 
(55, 56). Contrary to most normal tissues, over 80% of human cancers show expression and 
activity of telomerase (57).   
 
1.5 Telomerase independent telomere elongation 
Although telomerase is the most prevalent mechanism used for maintenance of 
telomeric DNA, a small percentage of tumors and immortalized cell lines have been described 
that do not contain telomerase activity. These lines utilize an Alternative Lengthening of 
Telomere (ALT) mechanism to circumvent the telomeric checkpoint (58). Characteristics of 
human ALT cells include great heterogeneity of telomere size (ranging from undetectable to 
abnormally long) within individual cells, and ALT-associated PML bodies (APBs) that 
contain extrachromosomal telomeric DNA, telomere-specific binding proteins, and proteins 
involved in DNA recombination and replication (59). Activation of ALT during 
immortalization involves recessive mutations in genes that are as yet unidentified. Evidence 
from unicellular eukaryotes suggests that recombination between telomeric repeats may be 
one mechanism for telomerase-independent telomere stabilization. Although the molecular 
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mechanism for telomere maintenance in the absence of telomerase remains speculative, new 
results from mammalian systems also implicate a mechanism based upon homologous 
recombination in the ALT pathway (58).  
 
1.6 Telomere shortening and M1/M2 model of cellular senescence and crisis 
Replicative senescence was first described more than 30 years ago, for human 
fibroblasts in culture and has been called the Hayflick limit (19). The number of divisions that 
normal cells complete before they senesce depends on the species, age and genetic 
background of the donor, as well as the particular cell type (5, 20, 21). Upon completing a 
finite number of divisions, cell growth is arrested with G1 content in human cells (60, 61) and 
G1 or G2 content in mamallian cells (62).  Once thus arrested, they cannot be stimulated to 
enter the S phase of the cell cycle by any known combination of physiological mitogens. This 
stage of a permanent cell cycle arrest has been termed cellular senescence.  
 
 
Figure 1.6.1 Induction of cellular senescence after a finite number of divisions due to 
telomere shortening in the absence of telomerase activity 
 
 
A two-stage model of cellular senescence M1/M2 has been proposed and the tumor 
suppressors p53 and Rb/p16 are part of the first mortality stage M1 or replicative senescence 
(54, 63). M1 is initiated when a few telomeres become shortened to a critical level and the 
chromosome ends become recognized as DNA damage signals leading to an activation of cell 
cycle check-points. In the absence of the gene products inducing these check-points (e.g. p53 
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or p16/Rb), cells continue to divide despite the prevalence of telomere dysfunction and 
ultimately reach a second checkpoint termed the “crisis” point (M2) which is characterized by 
massive rates of cell death and chromosomal instability (54). First experimental evidence for 
a relationship between telomere length and senescence was provided by the observation that 
telomeres of cultured somatic cells continuously shorten until cell growth is arrested at the 
M1 stage (19, 54). Experimental proof for the telomere hypothesis of cellular aging has come 
from experiments showing that the ectopic expression of hTERT leads to cellular 
immortalization and a bypass of senescence (64).  
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Figure 1.6.2 M1/M2 model of cellular senescence (65) (Linskens MH, Harley CB, West MD, 
Campisi J, Hayflick L. Replicative senescence and cell death. Science 1995, 267, 17). 
 
1.7 The DNA-damage hypothesis of telomere dysfunction 
A current hypothesis is that critcal telomere shortening leads to  telomere shortening 
and dysfunctional telomeres and this uncapping of chromosomal ends trigger responses 
similar to DNA-damage signaling including the p53-dependent DNA-damage pathway that 
leads to growth arrest or apoptosis (12-16, 62, 66). p53 DNA binding activity and 
transcriptional activity have been reported to increase upon replicative senescence. Moreover, 
p21, a well-recognized p53 target gene whose expression markedly increases in senescent 
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cells (67, 68). An important question concerns the signaling components upstream of p53 and 
p16/Rb that alert cells to telomere dysfunction. The ATM kinase is likely to be involved in the 
induction of senescence as well as in apoptosis. So far there is no suggestion on how the 
expression level of p16 is increased in cells experiencing telomere damage or other forms of 
DNA damage. In each case, p53 and p21 are induced and high levels of p16 accompany a 
reduction in pRb phosphorylation (67, 68). Perhaps the irreparable damage caused by the 
uncapping of multiple telomeres mimics by the ultimate consequences of extensive genome-
wide radiation damage. Telomere-directed senescence may thus reflect the results of 
persistent damage, irrespective of its original proximate cause. In accordance with this 
hypothesis a recent study shows that critical telomere shortening in senescent cells activate 
DNA damage checkpoint responses which are similar to the responses induced by cells 
bearing DNA double-strand breaks. This involves telomeric foci of phosphorylated histone 
H2AX and their co-localization with DNA repair and DNA damage checkpoint factors such 
53BP1, MDC1 and NBS1 and activation of CHK1, CHK2, MDC1 which are all down stream 
targets of ATM and p53 (16). 
 
In mTERC-/- mice, an in vivo model to study the impact of telomere shortening, the 
cell cycle inhibitor p53 has been identified as a mediator of adverse effects of telomere 
shortening in organ regeneration in vivo (62). Deletion of p53 in mTERC-/- mice rescued 
defects in homeostasis of high-turnover organs without rescuing telomere length, 
chromosomal capping, or fusions of the chromosomes. This observation suggests p53 as a 
downstream target of telomere dysfunction in vivo by inducing apoptosis or cell cycle arrest 
in response to critical telomere shortening (62). Interestingly the activation of p53 in response 
to telomere shortening might in part be independent of ATM. The ATM-/- mTERC-/- mice 
have premature aging phenotype and impaired organ homeostasis and show no rescue of these 
phenotypes as has been found in p53-/- mTERC-/- mice (69). Another mediator of apoptosis 
induced by telomere dysfunction in mTERC-/- mice is Ku86 (36), which plays a role in non-
homologous endjoining. Absence of Ku86 prevents chromosomal fusions and apoptosis 
induced by telomere dysfunction but does not rescue the growth deficit of cells and organs 
with critically short telomeres (70). These studies from mTERC-/- mice have given the first 
experimental evidence that telomere dysfunction acts upon regeneration process in vivo 
during aging and in response to acute or chronic injury. 
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1.8 The phenotypic and molecular characteristics of cellular senescence 
Cellular senescence induced by telomere shortening is characterized by typical 
changes in cell morphology and size (flattened cells with enlarged cytoplasm) (19, 71), and 
senescence-associated beta-galactosidase (SA-β-Gal) activity at pH6 (72). The findings on 
molecular level suggest that once cells undergo replicative senescence they express one or 
more inhibitors of cell cycle progression that can act in a trans-dominant manner (68).  The 
growth arrest associated with cellular senescence has been studied most extensively in 
cultured human fibroblasts (19-21, 60). It is clear from these studies that many genes, 
including at least three proto-oncogenes, remain mitogen-inducible in senescent cells (73). 
Thus senescent cells do not fail to proliferate due to a general breakdown of growth factor 
signal transduction.  Rather, it is now known that replicative senescence causes the selective 
repression of a few positive-acting, growth regulatory genes whose expression has been 
shown to be important for G1 progression and DNA synthesis.  In fibroblasts, these inhibited 
genes include the c-fos proto-oncogene (74), the helix-loop-helix ID-1 and ID-2 genes (75), 
and the E2F-1 and E2F-5 (76, 77) components of the E2F transcription factor.  In addition, the 
retinoblastoma tumor suppressor protein (pRb) remains in its growth suppressive form (that 
is, remains constitutively underphosphorylated) (78, 79). Phosphorylation of pRb during G1 
phase is carried out by cyclinD-Cdk4/6 and cyclin E-Cdk2 complexes (79). Phosphorylation 
of Rb is an essential event for the release of E2F transcription factors that promote the 
expression of late G1 genes whose products are required for S-phase initiation and 
progression (79). In addition to these deficiencies in positive growth-regulators, senescent 
human fibroblasts over-express two negative growth regulators: the p21 and p16 inhibitors of 
cyclin dependent protein kinases (CDKs) (67). In senescent cells even though there is 
abundant cyclin D-Cdk4/6 and cyclin E-Cdk2  complexes they lack cyclin D and cyclin E 
associated kinase activities which is due to increased inhibitory binding of p21 to these 
complexes rather than inhibitory phosphorylation of  kinase activity (67). The high levels of 
p21 and p16 are very likely responsible for the accumulation of inactive CDK complexes (67, 
68), and thus the constitutive under phosphorylation of pRb in senescent cells.  Furthermore, 
because p21 can inhibit E2F by both pRb dependent and pRb-independent mechanisms, the 
high level of p21 may well be also responsible for the lack of E2F activity in senescent cells 
(67, 68). However, in addition to this essentially irreversible arrest of cell proliferation, 
senescent cells display two other striking phenotypic changes.  First, senescent cells acquire 
resistance to apoptotic stimuli (80).  The mechanism by which senescent cells resist apoptotic 
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death is not well understood. Second, senescent cells show sometimes striking changes in 
differentiated functions with altered chromatin re-organization (81). Very little is known 
about the mechanisms that lead to chromatin remodeling and differentiated gene expression in 
senescent cells. 
 
The senescent phenotype
Irreversible Apoptotic 
growth arrest resistance
Altered differentiated 
function 
 
Figure 1.8.1 Characteristics of cellular senescence. (82) (Itahana K, Dimri G, Campisi J. 
Regulation of cellular senescence by p53. Eur J Biochem. 2001, 268, 2784-91).  
 
1.9 Premature senescence 
Beside induction of cellular senescence by critical telomere shortening, several other 
factors include oxidative stress, DNA damaging agents and uncontrolled stimulation of several 
mitogenic pathways can also induce senescence irrespective of telomere length (83-86). An 
example of such premature senescence is the induction of a permanent growth arrest by over-
stimulation of the ras/raf/MEK/MAPK pathway (86).  This arrest involves similar signaling 
pathways as the senescence program induced by critical telomere shortening and both 
programs have the same morphological markers (87). In primary human cells this premature 
senescence program leads to activation/upregulation of p53 and p16 (84, 86) and this 
"premature senescence program" has been implicated to function as a tumor suppressor 
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mechanism, preventing growth of cells with deregulated ras signaling (87). In addition, the 
"premature senescence" program gives a plausible explanation for the telomere independent 
onset of senescence in primary cell cultures indicating that abnormal mitogenic signaling 
induced by growth factors in the culture medium provokes a mitogenic stress-induced 
senescence response similar to the over-stimulation of the ras pathway (88, 89). Another 
stress-condition that has been linked to activation of a senescence program is oxidative stress 
and DNA-damage (83). It has been demonstrated that oxidative stress can co-operate with 
senescence induced by telomere shortening (90) whereas low oxygen condition can extend the 
lifespan of primary mouse embryonal fibroblasts (91). According to this finding the activation 
of senescence might depend on multiple factors including cellular stresses and telomere 
shortening. In line with this hypothesis, a recent study has shown that in primary human 
fibroblasts the activation of senescence during in vitro passage represents a mix of different 
senescence stimuli including oxidative and mitogenic stresses as well as telomere shortening 
(92). The inter-connection between these different senescence stimuli has yet to be explored.  
 
Replicative senescence Premature senescence  
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Figure 1.9.1 Replicative senescence and premature senescence are indistinguishable to each 
other and share common morphological as well as molecular markers of senescence (87) 
(Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the 
control of cell cycle checkpoints. Ann N Y Acad Sci. 2000, 908, 111-25). 
 
1.10 mTERC knock-out mouse: An invaluable model system for the study of the impact 
of telomere shortening in vivo 
The first animal model system to study the consequences of telomere shortening at 
organismal level in vivo was the telomerase deficient mice lacking the RNA component of 
telomerase (mTERC-/-), which is essential for telomerase activity (93). The telomerase 
function was not required for normal murine growth and development. The first generation 
(G1) mTERC-/- mice lack telomerase activity but – due to very long telomeres in laboratory 
mice do not show a significant phenotype (94). However, after breeding successive 
generations of telomerase-deficient mice, multiple phenotypes were uncovered in late 
generation mice (G3-G6), including defects in cell proliferation, wound healing, and the 
apoptotic loss of spermatogonia resulting in sterility (94, 95). In addition the phenotypes 
associated to telomere dysfunction include: elevated rates of embryonic mortality due to a 
defective closure of the neural tube (96), small size and severe intestinal atrophy (97), spleen 
atrophy and reduced proliferation of B and T lymphocytes upon mitogenic stimulation, as 
well as impaired germinal center function upon immunization (97).  
 
In response to chronic liver damage, mTERC-/- mice prematurely develop cirrhosis -- 
the end stage of chronic liver diseases in humans (98). In addition, the mice show premature 
aging of highly proliferative organs and a curtailed stress response leading to a reduced 
lifespan (99). The prevalence of premature aging phenotypes depends on the telomere length 
(99) and appears in earlier generations of mTERC-/- inter-crosses in mouse strains with shorter 
telomeres as compared to those with longer telomeres (97). In addition, it has beeen shown 
that regenerative defects in mTERC-/- mice are caused by the prevalence of very short 
telomeres independent of the average telomere length (100). Overall, these results support an 
essential role of telomeres and telomerase for the well-being and survival of organisms (93-
100). 
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1.11 Liver regeneration: An in vivo model system for the study of cell cycle initiation and 
progression 
Liver has unique ability to regulate its growth and mass.  Adult hepatocytes are 
normally quiescent and remain in G0 stage of the cell cycle but their ability to divide is not 
lost and they readily enter cell cycle in response to injury (101, 102). Therefore, hepatocytes 
constitute a conditional renewal cell system that may proliferate in vivo under well-defined 
conditions. This capacity is of physiological relevance in numerous liver diseases such as 
viral and alcoholic hepatitis, metabolic disorders, and post-liver surgery. Partial hepatectomy 
(70% liver resection) is a widely used method to study liver regeneration in animals. Liver 
regeneration following partial hepatectomy (PH) usually does not require the activation of 
liver precursor (´´stem``) cells.  Instead, liver mass is replenished by the proliferation of adult 
hepatocytes. After PH the remnant liver cells enter the cell cycle in a highly synchronized 
manner and restore the lost mass in 1 to 2 rounds of cell division within a week (101, 102). 
This makes it a highly valuable model system to study the cell cycle initiation and progression 
under in vivo conditions. The term regeneration is not biologically correct because the 
removed lobes or segments do not grow back.  Instead, restoration of liver mass occurs by the 
compensatory hyperplasia of the cells in the remaining lobes. During liver regeneration the 
liver cells continue to perform crucial metabolic functions such as glucose regulation, 
synthesis of many blood proteins, secretion of bile, and biodegradation of toxic compounds 
required for homeostasis (101).  
 
Liver regeneration is a multi-step process with at least two critical steps: the transition 
of the quiescent hepatocytes into the cell cycle (priming) and the progression beyond the 
restriction point in the G1 phase of the cell cycle (101).  A large number of genes are either 
newly expressed or increase their expression during liver regeneration after PH. The first 
phase of gene expression after PH, referred to as the immediate early phase, occurs very 
rapidly after the operation and lasts for approximately 4 hrs (101, 103).   The second phase of 
gene expression after partial hepatectomy is referred to as delayed early gene response. 
Extensive work by Taub and colleagues identified and defined the roles of as many as 70 
genes participate in the immediate early response to PH. The proto-oncogenes c-fos, jun-B, c-
jun and c-myc were the first genes to be identified in this group (104). During this phase the 
cells become competent to enter cell cycle and acquire the capacity to respond to a set of 
factors that make the cells progress through the G1 phase and replicate. The factors include 
IL-6, hepatocyte growth factor (HGF), epidermal growth factor (EGF), tumor necrosis factor 
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α (TNF-α), transforming growth factor- α, insulin, and other receptor ligands that have been 
implicated in various stages of hepatocyte proliferation.  These ligands, through complex 
molecular mechanisms, activate transcription factors including NF-κB, signal transducer and 
activator of transcription 3 (STAT3), activator protein 1 (AP-1), and CCAAT/ enhancer-
binding protein (C/EBP)β that initiate a cascade of gene expression that ultimately is 
responsible for proliferation (101, 105).   
 
Cell cycle genes activated after PH include p53, mdm2, p21, cyclins and cyclin 
dependent kinases (106).  The increased abundance of p21, an inhibitor of the cell cycle after 
growth stimulation by cyclin D1, reflects the characteristic feature of liver regeneration after 
partial hepatectomy that is, not only stimulators but also repressors are activated.  Examples 
of cell cycle repressors activated after partial hepatectomy include TGFβ, activin, p21 and p53 
(106).  Perhaps it is the dual activation of stimulators and repressors that makes liver 
regeneration a precisely regulated growth process that never goes beyond its predicted end 
point.   
 
The highly synchronized proliferation of more than 90% of remnant liver cells after 
PH not only provide an opportunity to study the cell cycle initiation and progression under in 
vivo conditions, but also gives an opportunity to study the role of different genes in different 
phases of cell cycle progression. Similarly, since telomere shortening affects the proliferative 
capacity of cells it is possible to identify the consequences of telomere shortening on cell 
cycle initiation and progression in vivo by using the liver regeneration system.  
 
1.12 Telomere shortening in aging and disease  
The telomere hypothesis of cellular aging has fueled speculations whether telomere 
shortening impacts on the regenerative capacity of tissues and organs during aging and 
chronic disease. In line with this hypothesis a variety of studies have shown telomere 
shortening during aging in a variety of human tissues and organs including liver (107-112). In 
addition, it has been demonstrated that different chronic diseases which induce elvated rates 
of cell turnover also induce accelerated telomere shortening. One example is accelerated 
telomere shortening in chronic liver disease (111,113) especially at the cirrhosis stage (114). 
These studies indicated that the telomere hypothesis of cell aging might apply to the 
development of liver cirrhosis at the end of chronic liver disease. Further support for this 
hypothesis came from the observation that the p53/p21-pathway is activated in liver cirrhosis 
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(115). The p53/p21 pathway is the major signaling pathway mediating the replicative 
senescence stage in response to critical telomere shortening (see above).  The observation of 
telomere shortening in chronic liver disease and cirrhosis is in accordance with the fact that 
cell turnover is elevated during this process (116) while telomerase is not active in human 
liver due to the lack of TERT-expression (117). Despite the evidence that telomere shortening 
might limit liver regeneration in humans it remains an open question whether telomere 
shortening is in fact affecting hepatocytes. Given the massive changes in organ architecture at 
the cirrhosis stage it remains a possibility that changes in telomere length at this stage would 
simply reflect differences in telomere length between different cell types.  
 
1.13 The impact of telomere shortening on liver regeneration in telomerase deficient 
mice.  
Previous studies on liver regeneration in mTERC-/- mice gave the first experimental 
support for the telomere-hypothesis of cirrhosis formation (98).  In these studies three 
different models of liver regeneration were analyzed: 1. Synchronized proliferation of 
hepatocytes in response to partial hepatectomy (PH), 2. Clonal expansion of hepatocytes  in 
the model of acute liver failure in albumin-urokinase-plasminogen-activator transgenic mice, 
and 3. Continuous destruction and concomitant proliferation of hepatocytes in the carbon 
tetrachloride model of chronic liver damage. In all three model systems telomere shortening 
significantly impaired the regenerative capacity of the liver resulting in reduced survival in 
the model of acute liver failure and the development of premature liver cirrhosis in the model 
of chronic liver damage (98). Impaired liver regeneration correlated with an increased 
frequency of anaphase bridges (a prominent sign of telomere dysfunction) (118), with 
perturbed cell cycle progression during the G2/M stage of the cell cycle, and with an elevated 
rate of hepatocyte apoptosis (98). Interestingly the adenoviral mediated gene delivery of 
mTERC to the liver of mTERC-/- mice rescued telomere dysfunction, and the premature 
development of liver cirrhosis by re-activating telomerase (98).  These data indicated that 
telomerase gene delivery can rescue cirrhosis formation which is induced by critical telomere 
shortening in vivo.  But it is not known about the consequences of telomere shortening on the 
other stages of cell cycle. 
 
1.14 Summary and the focus of present study 
Telomere shortening is prevalent during aging, chronic diseases of elevated cell turn 
over and appears to be an inevitable consequence in the absence of telomerase. From a variety 
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of studies it is clear that telomere shortening affects cell proliferation which in turn affects 
regeneration of tissues and organs. mTERC-/- mouse is an invaluable model system to study 
the consequences of telomere shortening in vivo. The DNA damage response pathways 
involving ATM, p53 and and their down stream targets and their associated factors are known 
to be involved in telomere shortening induced replicative senescence. 
 
A further understanding on the signaling and consequences of cellular senescence 
could lead to new therapeutic approaches to treat regenerative defects during aging and 
chronic diseases. Our study focussed on exploring the consequences of telomere shortening 
on cell cycle initiation and progression in vivo by analyzing liver regeneration in response to 
partial hepatectomy (PH) in late generation mTERC-/- mice and mTERC+/+ control mice. The 
study focussed on the impact of telomere shortening at G1/S transition stage of regenerating 
liver cells and anlysed the gene expression changes induced by telomere shortening at this cell 
cycle stage. In addition, we focused on the question whether telomere shortening induced 
replicative senescence signaling is constitutively operative at the same intensity irrespective 
of external factors or modulated by mitogen stimulation which induces a proliferative 
response. 
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2. Materials and Methods 
2.1 Chemicals 
Chemical              Supplier
Acetone Merck 
Agarose (Electrophoresis grade) Gibco 
Agarose (Sea Plaque) Gibco 
Ammonium acetate AppliChem 
Ammonium sulphate Merck 
Ampicillin Sigma 
ATP (adenosin tri-phosphate) Sigma 
Bacto-Tryptone Gibco 
BES (N,N-bis (2-Hydroxyethyl)-2 aminoethansulfonsyre) Sigma 
5’-bromo-2’-deoxyuridine (BrdU) Sigma 
Bromophenol blue Serva 
BSA (Bovine Serum Albumin)  Sigma 
Calcium chloride  Merck 
Chloroform  J.T.Baker 
Citric acid Merck 
3, 3’-diaminobenzidine tetra-hydrochloride (DAB) Amersham 
Deionised water Ampuwa 
Dimethyl formamide (DMF) Sigma 
Diethyl pyrocarbonate (DEPC) Sigma 
Dimethyl sulfoxide (DMSO)  Sigma 
dNTPs Invitrogen 
EDTA (N,N;N‘,N‘-Ethylenediaminotetraacetate) Merck 
Ethanol  J.T.Baker 
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Ethidium bromide  Sigma 
Eosin Y solution aquoes Sigma 
Ficoll Sigma 
Formaldehyde Merck 
Formamide Merck 
Glucose Sigma 
Glycerol  Serva 
Glycine AppliChem 
Glutaraldehyde Sigma 
Hemalum solution Merck 
Hepes (2-(4-(2-Hydroxyethyl)-1-piperazinyl)ethansulfonsyre)  ICN 
Hydrochloric acid  Merck 
Hydrogen peroxide Merck 
Hygromycine Sigma 
Isopropanol  J.T. Baker 
IPTG (Isopropyl-beta-D-thiogalactopyranoside) Roth 
Magnesium chloride  Merck 
Magnesium sulphate  Merck 
Mayer’s Haematoxylin solution Sigma 
Methanol  J.T.Baker 
MOPS (3-(N-Morpholin)propansulfonsyre Sigma 
Mounting medium for fluorescence Vectashield 
Mounting medium with DAPI Vectashield 
Paraformaldehyde Merck 
PBS (phosphate buffered saline) Gibco 
Potassium chloride  Merck 
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Potassium hexacyanoferrate (II)  Merck 
Potassium hexacyanoferrate (III)  Merck 
Propidium iodide Sigma 
RNA Clean Hybaid 
RNAse Away Roth 
Roti-phenol/Chloroform  Roth 
Sodium hydroxide  Merck 
Sodium acetate  AppliChem 
Sodium chloride  Merck 
Sodium dodecylsulphate (SDS) Sigma 
Sodium fluoride  Merck 
Sucrose Merck 
SYBR Green Sigma 
Tris (Tris-(hydroxymethyl)-aminomethane) AppliChem 
Triton-X-100 Sigma 
Tryptose phosphate broth Gibco 
Tween 20 Sigma 
X-gal (5-Bromo 4-chloro 3-indolyl- beta-D-galactopyranoside) Roth 
 
 
2.2 Radioactive material 
32P-γ-ATP        Amersham 
 
2.3 Molecular markers 
2.3.1 DNA-Markers 
100 bp-ladder       New England biolabs 
1 kb-ladder        Life technologies 
High molecular weight marker    Life technologies 
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2.3.2 RNA-Markers 
RNA ladder (RNAI)      Roche 
 
2.4 Enzymes 
Collagenase       Sigma 
Dispase       Sigma 
DNase I, RNase-free       Boehringer, Mannheim 
Hot star Taq polymerase     Qiagen 
Lysozyme       Sigma 
Proteinase K       Invitrogen 
Pepsin        Sigma 
Restriction Endonucleases      New England, Biolabs 
RNAse A       Sigma 
Superscript II-RT      Invitrogen 
T4 DNA ligase      Invitrogen 
T4-Kinase (Polynucleotide-Kinase)     New England, Biolabs 
Taq DNA polymerase     Qiagen 
 
2.5 Antibodies 
Anti-mouse-BrdU Antibody      Amersham 
Anti-BrdU-FITC Antibody       Beckton Dickinson 
FITC-conjugated goat anti-mouse IgG   Dako 
Peroxidase anti-mouse IgG2a    Amersham  
 
2.6 Tissue Culture Reagents 
DMEM with Glutamax-1     Gibco 
Foetal Bovine Serum (FBS)     Gibco 
Trypsine/EDTA solution     Biochrom 
Pencillin/Streptomycine     Biochrom 
 
2.7 Oligonucleotides 
All the oligonucleotides were purchased from MWG Biotech. (NC, USA). 
 
 
 30
  Materials & Methods   
Gene Primer-pairs 
Mouse-
Nucb2 
*5’-TTTGAACACCTGAACCACCA-3’ 
**5’CCGGTCATATTGCTCCAGAT-3’ 
Mouse-
Prkri 
*5’CCGACCTCACCAAAGTGATT-3’ 
**5’-TTCGTCAAGCTTCCCTTGTT-3’ 
Mouse-
Plk 
*5’-CTTCCTGAACGAGGATCTGG-3’ 
**5’-AGGAGTGCCACACAAGGTCT-3’ 
Mouse-
P21 
*5’-TTGTCGCTGTCTTGCACTCT-3’ 
**5’-AATCTGTCAGGCTGGTCTGC-3’ 
Mouse-
Gadd45g 
*5’-GGACCCTGACAATGTGACCT-3’ 
**5’-AGCAGAACGCCTGAATCAAC-3’ 
Mouse-
Faf1 
*5’-GGAGCAGATTCGCAAAGAAC-3’ 
**5’-CAGGCTCAGCATTTTCTTCC-3’ 
Mouse-
Wee1 
*5’-AACGGGCACTCTTCACAGAT-3’ 
**5’-GCTGACAGAGCGGTTCATTT-3’ 
Mouse-
Klf4 
*5’-ATGCAGTCACAAGTCCCCTC-3’ 
**5’-GACCTTCTTCCCCTCTTTGG-3’ 
Mouse-
p16 
*5’-TCTGCTCAACTACGGTGCAG-3’ 
**5’-CACCAGCGTGTCCAGGAAG-3’ 
Mouse-
ARF 
*5’-GCTCTGGCTTTCGTGAACAT-3’ 
**5’-GTGAACGTTGCCCATCATC-3’ 
Mouse-
rsp9 
*5’CTGGACGAGGGCAAGATGAAGC-3’ 
**5’-TGACGTTGGCGGATGAGCACA-3’ 
Human-
P21 
*5’-GCGACTGTGATGCGCTAAT-3’ 
**5’-GTCACCCTCCAGTGGTGTCT-3’ 
Human-
P16 
*5’-ACCAGAGGCAGTAACCATGC-3’ 
**5’-AAGTTTCCCGAGGTTTCTCA-3’ 
Human-
ARF 
*5’-CCAGGTGGGTAGAAGGTCTG-3’ 
**5’-GAGAATCGAAGCGCTACCTG-3’ 
Human-β-
actin 
*5’-GGACTTCGAGCAAGAGATGG-3’ 
**5’-AGGAAGGAAGGCTGGAAGAG-3’ 
 
* Forward primer **Reverse primer 
 
Telomere probe Cy3-OO-(CCCTAA)3   Applied Biosystems 
Oligo dT (TTTTTT)3 primer     MWG Biotech. 
Salmon Sperm DNA      Amersham 
 
2.8 Kits 
Cell proliferation kit      Amersham 
Gel extraction kit      Qiagen 
In situ cell death detection kit, Fluorescein   Roche 
Nucleotide removal kit     Qiagen 
Opt EIA set: Mouse IL-6     Pharmingen 
PGEM-T-Easy vector kit     Promega 
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Plasmid mini kit      Qiagen 
Plasmid maxi kit      Qiagen 
 
2.9 Other materials 
High density oligonucleotide chips    Affymetrix 
Bacterial Culture plates      Greiner 
Cell culture dishes (10cm)     Greiner 
Cell culture flasks (250ml)     Cell star 
Culture plates (6 well)     Cell star 
Centrifuge-Tubes, Ultra-ClearTM     Beckman 
Centrifuge tubes, sterile (10 ml)     Sarstedt 
Centrifuge tubes, sterile (50 ml)     Sarstedt 
FACS tubes       Falcon 
Film cassettes       Kodak 
Freezing vials       Nunc 
PCR soft tubes      Biozym 
Tissue Homogenizer       Braun 
3 MM Filter paper       Whatman 
 
2.10 Laboratory equipment 
Gene-chip scanner      Affymetrix 
Agilent Technologies 2100 Bioanalyzer    Agilent Technologies 
Cell culture incubator      Heraeus 
Cell culture laminar flow bench    Heraeus 
Cryostat Microm HM 500 OM     Omega 
Desktop centrifuge        Eppendorf 
Elektrophoresis-Apparatus       Labtech, Pharmacia Biotech 
FACS (FACScan)      Beckton Dickinson 
Fluorescence microscope     Olympus 
Gel doc       Biorad 
Heat block         Eppendorf 
Microscope       Olympus 
Microscope equipped camera    Sony 
Power-Supply         Biometra 
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PCR master cycler      Eppendorf 
ABI prism 7700 Sequence detection system   PE applied Biosystems  
Spectrophotometer        Contron 
Ti-70-Rotor und SW 28.1-Swinging-Bucket-Rotor    Beckman 
Ultra centrifuge      Beckman 
Vortex         Omnilab  
  
2.11 Mice  
Ten to twelve weeks old male G3 mTERC-/- and littermate mTERC+/+ (C57BL/6J 
strain) control mice were used for the in vivo experiments.  Late generation mTERC-/- mice 
were obtained by crossing successive generations of mTERC-/- until third generation (G3) 
(94). The mice were bred and maintained in the animal facility, Medical School, Hannover, 
on a standard diet and in 12 hrs of light-dark periods.   
 
2.12 DNA Extraction and Genotyping  
mTERC+/+, mTERC-/- and mTERC+/- mice were identified from the mouse colony by 
PCR amplification method. The DNA was extracted from the mice tails by standard Phenol-
Chloroform method. In brief, a small piece of tissue was cut from the tip of the mouse tail and 
digested in 500µl of lysis buffer (10mM NaCl + 10mM Tris-HCl (pH8.0) + 25mM EDTA 
pH8.0 + 0.5% SDS, 10ml of this buffer and 64µl of proteinase K) overnight with continuous 
shaking at 56ºC. Then 1 ml of phenol/chloroform was added and continuously but gently 
shaken for 1 min at room temperature and centrifuged at 10,000 rpm for 5 min. The 
supernatant was collected and 1ml of chloroform was added and continuously shaken for 10 
min at room temperature and centrifuged for 5 min at 10,000 rpm. To the supernatant 1 ml of 
iso-propanol was added (DNA precipitation) and gently shaken by inverting the eppendorf for 
1 min and then centrifuged at 13,000 rpm for 10 min. The supernatant was discarded and the 
DNA pellet was washed twice with 70% ethanol and centrifuged at 13,000 rpm for 5 min. The 
DNA pellet was air dried for 5 min and dissolved in 50µl of TE buffer (10mM Tris-HCl 
(pH7.6), 1mM EDTA). Primer pairs and the reaction conditions used for genotyping are as 
follows: mTRR-5’-TTCTGACCACCACCTACTTCAAT-3’, 5ppgK-5’-GGGGC 
TGCTAAAGCGCAT-3’, mTRwtF-5’ CTAAGCCGGCACTCCTTACAAG-3’. (1µg of DNA 
+ 2.5µl 10X PCR buffer + 1.5µl 3mM MgCl2 + 0.5µl dNTP’s + 1.0 µl mTRR primer (10 
pmol) + 1.0µl 5ppgK primer (10 pmol) + 1.0 µl mTRwtF primer (10 pmol) + 0.25µl Taq 
DNA polymerase + 15.25µl dH2O). The PCR cycle profile is as follows: initial denaturation 
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at 94ºC for 30 sec, annealing at 55ºC for 30 sec, and extension at 72ºC for 30 sec.  Thirty 
cycles of PCR amplification were performed and the PCR products were run on 2% agarose 
gel and visualized with ethidium bromide (25µl of 1mg/ml conc. for 100 ml of agarose gel). 
The primers amplify a fragment of 250bp for mTERC+/+ and 180bp for mTERC-/- and both 
the fragments for mTERC+/-. 
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ligature.  Care was taken to avoid disruption of the portal vein, biliary tract, and gallbladder.  
All animals resumed normal activities promptly after recovering from anesthesia.   After 2 
hours of BrdU pulse labeling mice were sacrificed at 24 (n=3), 30 (n=5), 32 (n=5), 36 (n=5), 
48 (n=5), 72 (n=5), 96 (n=5) and 120 (n=3) hrs after PH. For BrdU pulse labeling 10µl/gm 
body weight labeling reagent (10:1 ratio, 5-bromo-2-deoxyuridine and 5-fluro-20-
deoxyuridine, Cell proliferation kit, Amersham) was administered 2 hrs before sacrification.  
For continuous BrdU labeling (n=5) 0.8 mg/ml BrdU (Sigma) was given in sterile drinking 
water and fresh water was made after every 24 hours (Tough DF and Sprent J, 1994).  To 
increase the sensitivity of the continuous BrdU labeling procedure 200µL of 1mg/ml BrdU in 
PBS were administered intra-peritoneally in 12 hr intervals between 24-72 (or 120) hrs after 
PH.  After sacrification of the mice the liver lobes were snap-frozen in liquid nitrogen and 
stored at -80ºC until further use. 
 
2.14 Immuno-histochemical detection of BrdU  
7 µm thick cryostat-sections were fixed in Ice-cold acetone-methanol (1:1) for 10 min 
followed by two 5 min washes in TBS-Tween (20mM Tris-HCl, 137mM NaCl, 0.1% 
Tween20, pH 7.6).  The tissues were dehydrated in 70% ethanol for 30 min and air dried for 
about 30 min at room temperature.  The endogenous peroxidase activity was blocked by 
incubating the slides in 3% H2O2 in methanol for 10 min followed by two 5 min washes in 
TBS-Tween.  Denaturation of cellular DNA was done by immersing the slides in alkaline 
formamide (95ml formamide / 5ml 1N NaOH) for 30 sec at 70ºC followed by one 5 min wash 
in TBS-Tween at 70ºC followed by incubation in 15mM tri-sodium citrate in formamide for 
15 min at 70ºC.  The reaction was stopped by washing the slides in Ice-cold TBS-Tween 
twice, each wash for 5 min.  A second fixation was carried out in 3% formaldehyde in PBS 
for 30 min followed by two 5 min washes in TBS-Tween followed by incubation in 0.2% 
glutaraldehyde in PBS for 10 min at room temperature.  Then the slides were washed twice 
each wash for 5 min in TBS-Tween and incubated with anti-5-bromo-2’-deoxyuridine 
monoclonal antibody (Amersham) for over night at 4ºC in a wet chamber.  Then the slides 
were washed in TBS-Tween twice each wash for 5 min and incubated with peroxidase anti-
mouse IgG2a secondary antibody for 30 min at room temperature followed by three 5 min 
washes in TBS-Tween.  The detection was done by incubating them with the substrate 3, 3’-
diaminobenzidine tetrahydrochloride (25mg DAB / 100µL substrate intensifier / 50ml PBS), 
for 20 min followed by two washes each wash for 5 min with double distilled water.  Then the 
slides were counterstained with hemalum solution and mounted with mounting medium and 
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stored in dark until further analysis.  A BrdU labeling index was determined by counting the 
number of Brdu positive cells randomly in 20 low power magnification fields (10X) and 
expressing the number of BrdU labeled nuclei as a percent of all nuclei counted. 
 
2.15 Hematoxylin and Eosin (H&E) staining 
 7µm thick cryostat sections were prepared from paraffin embedded liver tissue 
samples. The sections were de-paraffinized by incubating them in xylene solution 3x5 min. 
Then the sections were fixed in acetone for 2 min on ice followed by rehydration by 
incubating them consequently in 100%, 90% and 70% ethanol and finally in dH2O each 3 
min. Then the slides were incubated in fresh hematoxylin for 15 min followed by washing 
with dH2O for 20 min. Then the slides were incubated with freshly prepared Eosin solution 
(which was acidified with acetic acid) for 1 min. Then the slides were washed with dH2O for 
5 min followed by dehydration in 90% ethanol followed by 100% ethanol each 3 min. Finally 
the slides were air dried for 5 min and mounted with mounting medium. 
 
2.16 Senescence Associated β-gal Staining  
Senescence-associated β-gal staining was carried out as described previously (72).  In 
brief, 7µm cryostat sections were fixed in 3% formaldehyde for 5 min, followed by three 
washes in PBS at room temperature.  The slides were incubated in freshly prepared SA- β-gal 
staining solution (1mg/ml of 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal) in DMF / 
40mM citric acid/sodium phosphate (pH 6.0) / 5mM potassium ferrocyanide / 5mM 
potassium ferricyanide / 150mM NaCl / 2mM MgCl2) at 37ºC for over night.  The stained 
sections were washed twice with PBS and counter-stained for 30 sec with eosin.  The excess 
counter-stain was removed by two washes in PBS.  All the samples were stained in triplicates. 
Analysis was done in blinded fashion.  The number of SA-β-gal positive cells was counted 
randomly in 20 low power fields (10X) and expressed the number of positive cells as a 
percent of all cells counted.  
 
2.17 BrdU and Telomere probe co-staining  
To combine BrdU staining with telomere probe Cy3-OO-(CCCTAA)3 hybridization, 7 
µm thick cryostat-sections were fixed in Ice-cold acetone-methanol (1:1) for 10 min followed 
by two 5 min washes in TBS-Tween (pH 7.6).  The tissues were dehydrated in 70% ethanol 
for 30 min and air dried for about 30 min at room temperature.  The endogenous peroxidase 
activity was blocked by incubating the slides in 3% H2O2 in methanol for 10 min followed by 
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two 5 min washes in TBS-Tween.  Denaturation of cellular DNA was done by immersing the 
slides in alkaline formamide (95ml formamide / 5ml 1N NaOH) for 30 sec at 70ºC followed 
by one 5 min wash in TBS-Tween at 70ºC followed by incubation in 15mM tri-sodium citrate 
in formamide for 15 min at 70ºC.  The reaction was stopped by washing the slides in Ice-cold 
TBS-Tween twice, each wash for 5 min.  A second fixation was carried out in 3% 
formaldehyde in PBS for 30 min followed by two 5 min washes in TBS-Tween. Then the 
tissues were digested with acidified pepsin (100mg pepsin / 100ml H2O / 84µL conc. HCl) for 
10 min followed by two 5 min washes in TBS-Tween.  Then they were fixed by incubating in 
0.2% glutaraldehyde in PBS for 10 min at room temperature.  Then the slides were co-
incubated with anti-5-bromo-2’-deoxyuridine monoclonal antibody (Amersham) and telomere 
probe hybridization mix [250µl final volume: 2.5µl 1M Tris-Cl, pH 7.2 / 21.4µl MgCl2 
(25mM MgCl2 / 9mM citric acid / 82mM Na2HPO4, pH7.4) / 175µl de-ionized formamide / 
12.5µl 10% (w/w) blocking reagent / 5µl 25µg/ml PNA Cy3-telomere probe / 33.6µL H2O] 
for over night at 4ºC in a wet chamber.  Then they were washed in TBS-Tween thrice each 
wash for 5 min and incubated with FITC-conjugated goat anti-mouse IgG secondary antibody 
(DAKO) for 30 min at room temperature followed by three 5 min washes in TBS-Tween.  
Then the slides were air dried for 10 min and mounted with 1:1 (v;v) mixed mounting 
solution with/without DAPI and stored in dark at 4ºC until further analysis.  The liver samples 
of the mice which were administered BrdU continuously until 120hrs were used for this 
double staining.  Five samples from each group (mTERC+/+ and G3mTERC-/-) were stained 
and analyzed at the same time. The quantification of the telomere fluorescence intensity was 
performed using TFL-TELO V1.0, a telomere analysis program developed by P.Landsdorp.   
 
2.18 SA- β-gal -BrdU co-staining 
For simultaneous detection of senescence and cell proliferation in the same sample, 
first SA-β gal staining at pH 6 was done (described above, 2.16) on 7µm sections of liver 
samples from mTERC+/+ (n=5) and G3mTERC-/- (n=5) followed by BrdU staining as 
described above. 
 
2.19 SA- β-gal -Telomere probe co-staining 
To measure the telomere lengths in senescent cells and proliferating cells in the same 
sample first SA-β gal staining was carried out (described before, 2.16) followed by telomere 
probe hybridization (described above, 2.17) except that the pepsin digestion step is optimized 
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to 7 minutes to detect cytoplasmic senescent staining and at the same time to minimize back 
ground for telomere fluorescence intensity measurement.  
 
2.20 Q-FISH on inter-phase nuclei of isolated hepatocytes 
In situ Q-FISH on interphase nuclei of liver cells was performed as described 
previously (120). The tissue sections were fixed in 4% paraformaldehyde in PBS. After three 
washes in PBS, a second fixation was carried out in 4% formaldehyde for 10 min at room 
temperature, followed by enzymatic unmasking of the sections for 10 minutes at 37ºC 
(enzyme mix: 100mg pepsin/ 50 mg collagenase / 100mg dispase / 84µl concentrated HCl / 
100ml water). Fixation and washing steps were repeated as described, followed by 
dehydration of the slides.  After 3 minutes of denaturation at 80ºC, the slides were incubated 
with hybridization mix: (125µl final volume): 2.5µl 1 M Tris-Cl, pH 7.2 / 21.4µl MgCl2 [25 
mM MgCl2 / 9mM citric acid / 8.2 mM NaH2PO4, pH7.4] / 175µl de-ionized formamide / 
12.5µl 10% (w/w) blocking reagent / 5µl 25µg / ml PNA Cy3-telomere probe). The slides 
were washed twice in washing solution I (100ml final volume: 70ml formamide / 1ml 1M 
Tris-Cl, pH7.2 / 1ml 10% BSA / 28ml dH2O), followed by three washes in washing solution 
II (15ml 1M Tris-Cl, pH 7.2 / 15ml 1.5 M NaCl / 120µl Tween 20 (0.08% final) / 120ml 
H2O). After dehydration, the slides were mounted with 1:1 (v:v) mixed mounting solution 
with/without DAPI. Pictures were taken at an exposure time of 1.5 seconds for the Cy3 
images and at 0.5 seconds for DAPI.   
 
2.21 Apoptotic TUNNEL assay  
The TUNNEL assay was performed on cryostat sections of frozen liver samples 
according to manufacturer protocol (In Situ cell death detection kit, Roche).  In brief 7µm 
cryostat sections were fixed in 4% para-formaldehyde in PBS, pH 7.4 for 20minutes at room 
temperature followed by two 15 minute washes with PBS.  Then the tissue sections were 
incubated in permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) for 5 
minutes on ice followed by 5minute wash with PBS.  50µL of tunnel reaction mix was 
applied directly on the top of the sections and incubated for 1 hour in a humidified chamber at 
37ºC.  Then the slides were rinsed 3x1min in PBS and mounted with 1:1 (v:v) mixed 
mounting solution with/without DAPI and analyzed under fluorescent microscope.  The 
number of apoptotic cells was counted in 20 high power fields (100X).  All the counts were 
performed without knowledge of the day(s) after partial hepatectomy. 
 
 38
  Materials & Methods   
 
2.22 Determination of IL-6 serum levels 
  Blood-sera were obtained from mice at 1, 3, 6, 9 and 12 hrs after partial hepatectomy 
and stored at -80ºC before testing.  Serum IL-6 levels were determined using Pharmingen 
OptEIATM Set: Mouse IL-6 kit according to manufacturer protocol.  In brief, the micro-wells 
of 96 well plate were coated with 100µl per well with capture antibody diluted in coating 
buffer (0.1M carbonate buffer, pH 9.5). Then the plate was sealed with paraffin and incubated 
at 4ºC over night with gentle shaking. Then the wells were aspirated and washed 3 times with 
300µl wash buffer per well (PBS with 0.05% Tween 20).  After the last wash the plate was 
inverted and blotted on to absorbent paper to remove any residual buffer.  Then the wells were 
blocked with 200µl assay diluent per well and incubated at room temperature for 1 hr. The 
wells were aspirated and washed 3 times with 300µl of wash buffer.  The standards and 
different dilutions of the samples were prepared and 100µl of each standard and sample were 
pipetted into appropriate well, sealed and incubated at room temperature for 2 hrs.  The wells 
were aspirated and washed 5 times with 300µl of wash buffer. Then 100µl of working 
detector (detection antibody + Avidin-HRP) was added to each well, sealed and incubated for 
1 hr at room temperature.  The wells were aspirated and washed 7 times with 300µl of wash 
buffer each wash 30 sec. Then 100µl of substrate solution was added to each well and the 
plate was incubated for 30 min at room temperature in the dark. Then the reaction was 
stopped by adding 50µl of stop solution (1M H3PO4 or 2N H2SO4).  The absorbance was read 
at 450nm within 30 min after termination of the reaction. 
 
2.23 RNA extraction and cDNA synthesis 
 The total RNA was extracted from the liver tissue and from the in vitro cultured cells 
according to manufacturer protocol (RNA CleanTM, Hybaid).  Briefly, the frozen liver tissue 
was homogenized with RNA CleanTM (2ml per 100mg tissue) in a glass-teflon homogenizer.  
200µL of chloroform was mixed per 2ml of homogenate and shaken vigorously for 15 sec. 
and incubated on ice for 5min.  The samples were centrifuged at 12,000xg at 4ºC and the 
upper aqueous phase was carefully transferred to a fresh tube and an equal volume of iso-
propanol was mixed to precipitate RNA and incubated for 15 min at -20ºC.  Then it was 
centrifuged for 15 min at 12,000xg at 4ºC and the supernatant was discarded without 
disturbing the RNA pellet.  The RNA pellet was washed with 70% ethanol and vertexed for 
few seconds and centrifuged for 8min at 7,500xg.  The washing step was repeated once again.  
The RNA pellet was dried under vacuum for 10 min and dissolved in suitable volume of 
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RNAase free DEPC water.  The quality of the RNA was checked on a denaturing agarose gel 
[(1.2gms agarose, 5 ml 20X MOPs buffer (400mM MOPs + 50mM sodium acetate + 10mM 
EDTA, pH 7.0 + 95ml dH2O, boiled and cooled to 50ºC and 1.8 ml of 37% formaldehyde and 
2 µl of 1mg/ml ethidium bromide were added] and run in the running buffer (50 ml 20X 
MOPs+20 ml 37% formaldehyde+930 ml dH2O). The concentration of the RNA was 
determined by spectrophotometer at 260nm (OD260).  The RNA samples having an OD260/280 
ratio of 2 or more were used for micro-array analysis, cDNA synthesis and Quantitative Real 
Time PCR. 2µg total RNA was used to synthesize cDNA with oligo-dT primer and 
Superscript II-RT enzyme (invitrogen).  The RT reaction was checked by amplifying a 130bp 
fragment of the house keeping genes RSP9 of mouse and β-actin of human.    
 
2.24 High density oligonucleotide microarray hybridization and analysis 
 Quality and integrity of the total RNA isolated from liver samples was checked by 
running all the samples on an Agilent Technologies 2100 Bioanalyzer (Agilent Technologies). 
Preparation of the biotinylated RNA probe was done as described (Affymetrix GeneChip 
Expression Analysis Manual, Affymetrix). Briefly, 5 µg total RNA was reverse transcribed to 
cDNA using 100 pmol of a T7T23V primer (Eurogentec; Seraing, Belgium) containing a T7 
promotor. The concentration of biotin-labeled cRNA was determined by UV absorbance. In 
all cases, 12.5 µg of each biotinylated cRNA preparation were fragmented and placed in a 
hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, 
and Cre) as recommended by the manufacturer. Samples were hybridized to an identical lot of 
Affymetrix MG-U74Av2 for 16 hours. After hybridization the GeneChips were washed, 
stained with SA-PE and read using an Affymetrix GeneChip fluidic station and scanner.  
Analysis of microarray data was performed using the Affymetrix Microarray Suite 5.0, 
Affymetrix MicroDB 3.0  and Affymetrix Data Mining Tool 3.0 at the Array facility of the 
German Research Center for Biotechnology, GBF, Braunschweig, Germany. All array 
experiments were scaled to a target intensity of 150, otherwise using the default values of the 
Microarray suite. Filtering of the results was done as follows: Genes are considered as 
regulated when their fold change is greater than or equal to 2 or less than or equal to 2, the 
statistical parameter for a significant change is less than 0.001 ( change p-Value for changes 
called increased (I)) or greater than 0.999 (change p-Value for changes called decreased (D)). 
Additionally, the signal difference of a certain gene should be greater than 100. 
 40
  Materials & Methods   
 
2.25 Liver perfusion, nuclei preparation and flow cytometry 
 Liver cells were collected by collagenase perfusion method. The cells were collected 
from the quiescent liver (non-operated) (n=5), 48hours (n=6) and 96hours (n=5) after PH 
from each group (mTERC+/+ and G3 mTERC-/-). Mice were anesthetized and subjected to 
70% partial hepatectomy and 10µL/gm body weight labeling reagent (10:1 ratio, 5-bromo-2-
deoxyuridine and 5-fluro-20-deoxyuridine, (Cell proliferation kit, Amersham) was 
administered 2 hours before liver perfusion. The abdomen of the mouse was wide opened and 
the liver was perfused through the portal vien by inserting SURFLO I.V catheter connected to 
ISMATEC pump with  KRBI buffer (150mM NaCl, 5mM KCl, 5mM glucose, 25mM 
NaHCO3, 20mM HEPES, 1mM EDTA, pH 7.4) until the blood is completely drained-out 
followed by KRBII (150mM NaCl, 5mM KCl, 5mM glucose, 25mM NaHCO3, 20mM 
HEPES, 0.5mM CaCl2, 0.5mg/ml of collagenase) until the liver mass becomes soft and 
fragile. The above two buffers were kept at 37º C during the perfusion. Then the liver mass is 
suspended in 10ml of PBS and the single cell suspension was achieved by gentle pipeting.  
Then it is centrifuged at 50 x g for 3 minutes and the pellet which contains >90% hepatocytes 
was collected for nuclei preparation.   
 
1 x 106 cells were suspended gently for 2 minutes without producing air bubbles in 2 
ml of NPBT buffer (10mM TrisCl pH 7.4, 2mM MgCl2, 140mM NaCl, 0.5% Triton-X-100) 
and centrifuged through a 50% sucrose gradient (50% sucrose in NPB, 10mM TrisCl pH 7.4, 
2mM MgCl2, 140mM NaCl) for 10 minutes at 13000 rpm.  The nuclear pellet was re-
suspended in suitable volume of PBS and again centrifuged at 50 x g for 2 minutes to remove 
non-lysed cells.  The pure nuclei obtained from this procedure were used for flow cytometry.  
. 
 
2.26 Propidium iodide (PI) staining for FACS analysis 
The isolated nuclei were re-suspended  in 1ml of 1% BSA in PBS and centrifuged at 
500x for 15 min at room temperature and the pellet was re-suspended in 200µl of PBS and 
then fixed in 5 ml of ice-cold 70% ethanol by adding ethanol drop by drop while vortexing 
and then incubated on ice for 30 min. Then the cells were centrifuged at 500x for 10 min at 
4ºC and the supernatant was aspirated and the pellet was re-suspended in 1 ml of 2N HCl + 
0.5% Triton-X100 (17.2 ml of Conc. HCl and 0.5 ml of Triton-X100 in 82.3 ml of H2O) at 
room temperature for 30 min and then centrifuged at 500x for 10 min and the supernatant was 
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aspirated and the pellet was re-suspended in 1 ml of 0.1M NaB4O7, pH 8.5 and then 
centrifuged at 500x for 10 min and re-suspended in 1ml of 0.5% Tween-20/1% BSA/PBS and 
the cell concentration was adjusted to achieve 1 x 106 cells/test.  Then it is centrifuged at 500x 
for 10 min and re-suspended in 0.5 ml of PBS + 5 µg (final conc.) of PI + 10 µl of 10 mg/ml 
RNase A. 
 
2.27 Anti-BrdU (FITC) -PI double staining for FACS analysis 
The isolated nuclei were re-suspend  in 1ml of 1% BSA in PBS and centrifuged at 
500x for 15 min at room temperature and the pellet was re-suspended in 200µl of PBS and 
then fixed in 5 ml of ice-cold 70% ethanol by adding ethanol drop by drop while vertexing 
and then incubated on ice for 30 minutes. Then the cells were centrifuged at 500x for 10 min 
at 4ºC and the supernatant was aspirated and the pellet was re-suspended in 1 ml of 2N HCl + 
0.5% Triton-X100 (17.2 ml of Conc. HCl and 0.5 ml of Triton-X100 in 82.3 ml of H2O) at 
room temperature for 30 min and then centrifuged at 500x for 10 min and the supernatant was 
aspirated and the pellet was re-suspended in 1 ml of 0.1M NaB4O7, pH 8.5 and then 
centrifuged at 500x for 10 min and re-suspended in 1ml of 0.5% Tween-20/1% BSA/PBS and 
the cell concentration was adjusted to achieve 1 x 106 cells/test.  Then the cells were 
incubated with 20µl of Anti-BrdU-FITC (Becton Dickinson) for 30 min per 106 cells at room 
temperature and then washed once in 1 ml of 0.5% Tween-20/1%BSA/PBS and centrifuged at 
500x for 10 min and re-suspended in 0.5 ml of PBS + 5 µg (final conc.) of PI + 10 µl of 10 
mg/ml RNase A. The nuclei collected from 0 hours and 21 days after PH were stained with 
only PI where as the nuclei from 48hrs and 96hrs after PH were double stained with PI and 
FITC-antiBrdU antibody (Becton Dickinson) as recommended by the manufacturer.  Flow 
cytometric analysis was carried out with FACScan (Becton Dickinson) equiped with 
Cellquest software. 
 
2.28 Quantitative real time PCR 
  Quantitative real-time PCR was performed on ABI Prism 7700 Sequence detection 
system (PE Applied Biosystems) by using SYBR Green I (Sigma S9430) as a double-strand 
DNA-specific binding dye.  Same RNA preparations from mice were used for micro-array 
analysis and quantitative RT-PCR.  All the samples were analysed in triplicates and the 
expression was confirmed by three independent PCR runs.  The cycle profile of PCR is as 
follows:  An initial 10 min activation of Hot Star TaqTM DNA polymerase (Qiagen) at 95ºC 
followed by denaturation at 94ºC for 15 sec, annealing at 54ºC for 15 sec, and extension at 
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72ºC for 30 sec.  45 cycles of PCR amplification were performed to confirm the expression 
level and the house keeping gene RSP9 was used as an internal control for mouse and β-actin 
for primary human fibroblasts to normalize the expression levels. As SYBR Green I is not 
specific for the PCR product and binds to primer dimers formed non-specifically during all 
PCR reactions, optimum temperature for analysis of specific product was obtained after 
amplification by raising the temperature successively through 0.5ºC steps and comparing the 
melting temperature of specific product with non-specific product obtained from a non-
template control (NTC). The optimum temperature determined from melting point analysis 
was then used for quantitative PCR.  The quantification data were analyzed with the ABI 
Prism 7700 analysis software. In all experiments the threshold value used to determine Ct 
during analysis was kept constant.  For each primer pair the linearity of detection was 
confirmed to have a correlation coefficient of at least 0.98 over the detection area by 
measuring a fourfold dilution curve with cDNA prepared from liver samples and from 
primary cells. Fold difference was therefore calculated assuming 100% efficient PCR where 
each Ct was normalized to the house keeping gene RSP9 or β-actin expression.  The results 
are shown as mean ± SD for three different PCR reactions.   
 
2.29 Cell culture 
 Human fetal lung fibroblasts (IMR 90), human embryo lung fibroblasts  (WI38) and 
human adult fibroblasts (HK1) were cultured in DMEM medium (Gibco) supplemented with 
10% FBS (Sigma) and 1% pencillin / streptomycin in a CO2 incubator (5% CO2 and 20% O2) 
at 37ºC. Cells were passaged serially in vitro and early passage and late passage cultures were 
used for this study. For experiments involving serum starvation and stimulation, cells were 
collected by trypsinization from serially passaged cultures of early and late passages and 
cultured in DMEM medium with 0.1% FBS for 120 hours and stimulated with 10% FBS in 
DMEM medium for 6, 12 and 24 hours.  For drug (PD098059) inhibition studies cells were 
cultured in 0.1% FBS for 120 hours and incubated with 10µM final concentration of 
PD098059 1 hour before serum stimulation. 
 
2.30 Retrovirus preparation and infection 
The onyx cells (packaging cell line) were cultured in DMEM medium with 10% FBS 
and were trasfected with vector DNA (pBABEhygro-hTERT) by calcium phosphate 
transfection (20 µg of plasmid DNA+125 µl of 1M CaCl2 with a final volume of 500 µl was 
bubbled into 500µl of 2X HBS (280mM NaCl, 10mM KCl, 1.5mM Na2HPO4.2H2O, 50mM 
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HEPES, pH 7.5). The medium was changed after 12 hours and 5 ml of fresh medium was 
given. After 24 hrs the medium was filtered through 0.45µm filter and 5µl of polybreen was 
mixed and the primary fibroblasts were infected with this medium. Second round of infection 
was done exactly like before, after 48 hours. Then the successfully infected cells were 
selected with hygromycine (80µg/ml) for one week. Fresh medium with drug was given after 
every 24 hrs. After one week the cells resistant to hygromycine were cultured in DMEM 
medium without drug. 
 
2.31 Cloning using the pGEMT-Easy vector 
 Cloning of desired amplified full length cDNAs into pGEMT-Easy vector was done 
according to manufacturer protocol (Promega). The ligation reaction was set up by mixing 5µl 
2X rapid ligation buffer, 1µl pGEMT-Easy vector, 1µl of PCR product, 1µl of T4 DNA 
Ligase and 2µl of dH2O. The contents were mixed and incubated for 2 hrs at room 
temperature. Then the ligation reaction tubes were briefly centrifuged to collect the contents 
at the bottom. Then 50µl high efficiency competent bacterial cells (JM 109, promega) were 
transformed with 2µl of the above reaction mix and incubated on ice for 20 min followed by a 
heat shock at 42ºC for 1 min. Then the tubes were immediately transferred to ice for 5 min. 
Then 950µl of LB broth medium was added and incubated at 37ºC for 2 hrs with shaking at 
150 rpm in an orbital shaker. 100µl of transformation culture was plated onto duplicate 
LB/ampicillin/IPTG/X-gal plates. Then the plates were incubated overnight (14-16 hrs) at 
37ºC. This system facilitates blue/white screening, and white colonies generally contain 
inserts. 
 
2.32 In-gel southern bloting for TRF (Telomere Restriction Fragment) length analysis 
Genomic DNA was extracted by phenol-chloroform method as described above 
(2.12). The DNA was rehydrated in TE buffer and an aliquot of undigested DNA was run in 
an agarose gel to check for DNA degradation. Only samples without any visible degradation 
were used for the assay. 15µg of total DNA was digested overnight at 37ºC (with 3µl of HinfI 
+ 12 µl of RsaI + 15µl NEB2 buffer with a final volume of 150µl with ddH2O). Complete 
digestion of the DNA samples was confirmed in a 1.5% agarose gel. Digested DNA was 
loaded into 0.8% agarose gel and run in TAE buffer overnight by applying 40V. Then the gel 
was carefully transferred on to a Whattman filter paper and vacuum drued at 60ºC for 45 min. 
Then the dried gel was denatured in denaturation buffer (1.5M NaCl + 0.5M NaOH) followed 
by neutralization in neutralization buffer (1.5M NaCl + 1 M Tris-Cl, pH 7.5), 20 minutes 
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each. Then it was blocked with pre-hybridization mix (2.5ml 20X SSC, 100µl Phosphate 
wash, 1ml 50X Denhard’s reagent, 6.4ml dH2O and 500µg Salmon sperm DNA) for 1 hour at 
37ºC followed by hybridization with radioactively labeled telomere probe (TTAGGG)3 for 4 
hours at 37ºC in a narrow closed glass tube. (The radioactive probe was prepared by 
incubating (1µl TRF3 (50ng), 13.5µl H2O, 2 µl PNK buffer, 2.5 µl γATP, 1 µl T4 PNK for 1 
hour at 37ºC followed by a short wash with 50µl of dH2O and then centrifuged through a 
micro-spin G-25 coulmn and then denatured at 95ºC for 10 min). After 4 hours the gel was 
washed three times each wash for 10 minutes with washing buffer (0.25X SSC pH 7.0 + 0.1% 
SDS). Then the gel was sealed into a plastic cover and exposed to Phosphoimager screen for 
over night in a Kodak film cassette. Then the film was read with Phosphoimager equipped 
with the software Bas Reader and PCBAS. All the calculations were performed with PCBAS 
and Microsoft Excel. 
 
2.33 LB (Luria-Bertani) medium 
For 1 litre LB medium, 10gms select peptone, 5gms yeast extract and 10gms NaCl 
was dissolved in 950 ml of de-ionized water and the pH of the solution was adjusted to 7.0 
with NaOH and then brought the volume to 1 litre with ddH2O. Then the solution was 
autoclaved on liquid cycle for 20 min at 15 psi. Then the solution was allowed to cool down 
to 55ºC and the antibiotic was added if it is required (50µg/ml of either ampicilin or 
kanamycin). Then the medium was stored at 4ºC in dark. 
 
2.34 LB (Luria-Bertani) plates 
LB medium was prepared as described before and then 15gms/L agar was added 
before autoclaving. Then the solution was allowed to cool down to 55ºC and the required 
antibiotic was added (50µg/ml of either ampicilin or kanamycin) and poured into 10 cm 
plates, let them hardened and then inverted and stored at 4ºC in dark. 
 
2.35 Bacterial transformation and culture 
100 ng of DNA was mixed with 100µl of competent bacterial cells and incubated on 
ice for 10 min. Then a brief 1 min heat-shock was given at 42ºC in a water bath followed by 
incubation on ice for 10 min. Then 100 µl of LB medium without any antibiotic was added 
and the solution was shaken vigorously in an orbital shaker for 1 hr at 225 rpm. Then 300µl of 
LB medium with required antibiotic (ampicilin or kanamycin) was added, mixed and 
centrifuged and the bacterial pellet was resuspended in 100µl of LB medium and plated on to 
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LB plates and incubated at 37ºC for overnight (12 to 14 hours). After that the plates were 
transferred to 4ºC to avoid further growth of bacterial colonies. To culture bacteria, a single 
colony was picked up with a sterile pipette tip and inoculated into 2.5ml LB medium with 
desired antibiotic and shaken vigorously in an orbital shaker overnight (12 to 14 hrs). 
 
2.36 Plasmid mini preparation 
1.5 ml of the above bacterial culture medium was taken into an eppendorf and 
centrifuged at 5000rpm for 5 min at room temperature. The supernatant was discarded and the 
bacterial pellet was re-suspended without producing air bubbles in 250µl of STET buffer 
(0.1M NaCl, 10mM Tris, 1mM EDTA, 5% Triton-100-X) and 10µl of lysozyme (10mg/ml) 
was added mixed and denatured at 95ºC for 45 sec and then transferred to ice immediately 
and incubated for 5 min. Then it is centrifuged at 13,000 rpm for 20 min at 4ºC and the 
supernatant was carefully transferred to a new eppendorf and the DNA was precipitated with 
ice cold iso-propanol and incubated at room temperature for 5 min and centrifuged at 13,000 
rpm for 20 min at room temperature. The supernatant was discarded and the DNA pellet was 
washed with 500µl of 70% ethanol and centrifuged at 8000 rpm for 10 min at room 
temperature and the washing step was repeated twice. The supernatant was discarded and the 
pellet was air dried for 10 min and then dissolved in 50µl of TE (10mM Tris-HCl, 1mM 
EDTA) buffer. 
 
2.37 Plasmid maxi preparation 
Plasmid maxi preparation was done by following Qiagen plasmid maxi kit 
manufacturer protocol. In brief 500µl of bacterial culture medium was inoculated into 200 ml 
of LB medium with desired antibiotic and continuously shaken for over night at 37ºC in an 
orbital shaker at 225rpm. Then it is centrifuged at 6000 rpm for 15 min at 4ºC and the 
supernatant was discarded and the pellet was re-suspended in 10 ml of buffer P1 and then 10 
ml of buffer P2 was mixed and incubated at room temperature for 5 min. Then 10 ml of 
chilled buffer P3 was added mixed immediately but gently by inverting 4 to 6 times and 
incubated on ice for 20 min and centrifuged at 20,000 rpm for 30 min at 4ºC and the 
supernatant containing plasmid DNA was collected and 2.5 ml of ER buffer was mixed and 
incubated on ice for 30 min. Then it is applied to a Qiagen-tip 500 which was already 
equilibrated with 10 ml of buffer QBT and allowed the column to empty by gravity flow.  
Then the Qiagen-tip was washed twice with 30 ml of buffer QC. Then the bound DNA was 
eluted with 15 ml of buffer QF. DNA was precipitated with 10.5 ml of room temperature iso-
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propanol and centrifuged at 15,000 rpm for 30 min at 4ºC. The supernatant was decanted and 
the pellet was washed with 70% ethanol and centrifuged at 8,000 rpm for 10 min.  The pellet 
was air dried and dissolved in 300µl TE buffer. 
 
2.38 Restriction digestion and insert verification 
1µg of DNA was digested with 1µl of restriction endonuclease (10U) in 2 µl of 
specific NEB buffer in a final volume of 10µl in dH2O at 37ºC in a water bath for 2 hrs. Then 
the reaction mixer is incubated at 65ºC to inactivate the enzyme. The insert of interest was 
checked by running the digest on 0.8% agarose gel and stained with ethidium bromide 
(20µl/100 ml of gel at 1mg/ml conc.) and compared with standard DNA markers of known 
size. 
 
2.39 PCR Product extraction from the agarose gel 
QIAquick Gel Extraction Kit and manufacturer protocol was followed for extraction 
of PCR products from the agarose gels. The DNA fragments were excised from the agarose 
gel with a clean sharp scalpel. The gel slice was weighed in a colourless tube and three 
volumes of Buffer QG was mixed with 1 volume of gel (300µl of Buffer QG to 100mg of gel 
slice) and incubated at 50ºC until the gel slice has completely dissolved. After the gel slice 
has dissolved completely, one gel volume of isopropanol was added to the sample, mixed and 
applied to the QIAquick column and centrifuged at 13,000rpm for 1 min at room temperature. 
Then the column was washed once with 750µl of Buffer PE and centrifuged at 13,000rpm for 
1 min at room temperature. The flow through was discarded and the column was centrifuged 
once again to remove any residual ethanol. The QIAquick column was placed into a clean 
1.5ml microfuge tube and the bound DNA was eluted with 30µl of dH2O and stored at -20ºC 
until further use. 
 
2.40 Freezing of cells 
The medium was discarded and the cells were washed once with PBS and trypsinized 
and re-suspended in 5 ml of fresh DMEM medium and centrifuged at 500 rpm for 10 min and 
the supernatant was discarded and the cell pellet was re-suspended in 1 ml of ice-cold freezing 
medium (90% FBS+10% DMSO), transferred to freezing vials (Nunc) and kept for 2 days at -
80°C in a freezing chamber (Nunc) allowing slow freezing of the cells at a rate of 
approximately -1ºC per hr. Finally the frozen cells were transferred to liquid nitrogen for long 
term storage. 
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2.41 Thawing of cells 
The freezing vials in which the cells were stored are quickly thawed at 37°C, re-
suspended in 5ml of fresh DMEM medium, centrifuged at 500rpm for 10 min and the cell 
pellet was resuspended in 10ml of medium and plated into culture dishes. 
 
2.42 Human liver cirrhosis samples and histology 
         All samples were derived from explanted livers of patients undergoing liver 
transplantation. Collection of the samples was approved by the ethical committee of the 
Medical School Hannover. All liver samples were snap frozen in liquid nitrogen within 30 
min after explantation and stored at -80°C until analysis. Histological analysis was performed 
on formalin-fixed paraffin embedded tissue samples at the Department of Pathology, Medical 
School Hannover. A collection of 64 samples from different cirrhosis groups AIH (n=12), 
Alcoholism (n=7), Viral hepatitis (n=12), PBC (n=7), PSC (n=13) and controls (n=15) were 
used for this study.  
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3. Results 
3.1 Telomere shortening limits the number of cells participating in organ regeneration  
The resting liver is a mitotically inactive organ with over 95% of the cells in the G0-
stage of the cell cycle. In response to partial hepatectomy (PH) liver cells re-enter the cell 
cycle in a highly synchronized fashion and regenerate lost mass by one to two rounds of 
replication within one week thus representing a system in which somatic cell division 
regenerates organ mass without a direct need for specific stem cell population (101, 102). To 
analyze the impact of telomere shortening on organ regeneration at the cellular level, 
continuous labeling of all the proliferating liver cells with BrdU was performed in G3 
mTERC-/- and mTERC+/+ controls until two rounds of replication (120hrs after PH) had been 
completed.  After the first (72hrs after PH) as well as the second (120hrs after PH) round of 
DNA-replication the number of cells participating in liver regeneration was significantly 
reduced in G3 mTERC-/- mice compared to mTERC+/+ mice (Figure 3.1.1A-B). These data 
indicated that telomere shortening inhibited a sub-population of liver cells from participating 
in organ regeneration.  
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Figure 3.1.1 The percentage of liver cells incorporating BrdU in response to PH under 
continuous BrdU labeling is higher in mTERC+/+ compared to G3 mTERC-/- mice. (A) Rate of 
BrdU-labeled liver cells at 72 hrs after PH: 83.83±7.44% in mTERC+/+ (n=5) vs 64.5±4.28% 
in G3 mTERC-/- (n=5), p<0.0001, and at 120 hrs after PH: 86.96±4.33 in mTERC+/+ (n=5) vs 
72.30±5.45% in G3 mTERC-/- (n=5), p<0.0001. (B) Representative photographs of BrdU 
staining pattern in mTERC+/+ and G3 mTERC-/- mice 120hrs after PH under continuous BrdU 
infusion (magnification bar: 150µm). 
 
Previous studies in late generation mTERC-/- mice have shown that telomere 
shortening leads to defective regeneration and impaired organ homeostasis (97-99).  To test 
whether inhibited cell cycle entry of a sub-population of cells in G3 mTERC-/- mice is due to 
critical telomere shortening or due to lack of telomerase itself we followed the percentage of 
replicating liver cells at the first peak stage of S-phase (48 hours) after PH in mTERC+/+, G3 
mTERC-/- and G1 mTERC-/- mice. G1 mTERC-/- mice lack telomerase activity but due to the 
long telomere length in mice do not have critically short telomeres and no signs of telomere 
dysfunction (93). As described above (Figure 3.1.1) the rate of BrdU-positive cells at the first 
peak stage of S-phase in response to PH was significantly decreased in G3 mTERC-/- mice 
compared to mTERC+/+ mice. In contrast, G1 mTERC-/- mice have very similar rates of BrdU-
positive cells compared to mTERC+/+ mice (Figure 3.1.2 A, 44.45±5.26% in G1 mTERC-/- 
mice compared to 47.03±6.33% in mTERC+/+ mice, p= 0.0934) indicating that not the 
absence of telomerase per se but the shortening of telomeres to a critical length inhibits a sub-
population of cells from participating in organ regeneration. To test whether telomerase re-
expression would rescue diminished organ regeneration induced by telomere shortening, G3 
mTERC-/- mice were crossed with mTERC+/- mice as described previously (121). With this 
approach the G4 mTERC-/- have characteristic critical short telomeres and telomere 
dysfunction whereas the G4 mTERC+/- mice have a rescue of telomere function due to 
telomerase re-expression. When mice of this intercross were exposed to PH G4 mTERC-/- 
offspring showed a decreased number of liver cells participating in organ regeneration. In 
contrast, liver regeneration in G4 mTERC+/- offspring was rescued to levels comparable to 
mTERC+/+ mice (Figure 3.1.2 B, rate of BrdU-positive liver cells 48 hours after PH: 
45.52±4.65% in G4 mTERC+/- offsprings compared to 29.90±3.25% in G4 mTERC-/- 
offspring, p<0.0001). These results indicated that telomere stabilization by telomerase re-
expression completely rescued impaired liver regeneration induced by inhibition of cell cycle 
re-entry in a subset of liver cells with critical short telomeres in mTERC-/- mice. 
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Figure 3.1.2 (A) Percentage of cells incorporating BrdU at the first peak stage of S-phase 
(48hrs after PH) under 2hrs of BrdU pulse labeling: 47.03±6.33% in mTERC+/+ (n=5) vs 
44.45±5.26% G1 mTERC-/- (n=5, p= 0.0934) and 32.31±6.65% G3 mTERC-/- (n=5, 
p<0.0001).  A significant reduction in the BrdU-index is evident in G3 mTERC-/- mice, 
whereas G1 mTERC-/- mice show a similar rate of BrdU positive liver cells compared to 
mTERC+/+ mice indicating that telomere length but not lack of telomerase impacts on the 
number of cells participating in organ regeneration. (B) Percentage of cells incorporating 
BrdU at the first peak stage of S-phase (48hrs after PH) under 2hrs of BrdU pulse labeling: 
45.52±4.65% in G4 mTERC+/- (n=5) vs 29.90±3.25% G4 mTERC-/- (n=5, p<0.0001). G4 
mTERC+/- mice show a rescue in the percentage of BrdU positive cells indicating that 
telomere stabilization by telomerase re-expression rescues suppression of cell cycle re-entry 
of a sub-population of cells. 
 
Together these data indicated that the phenotype of a decreased population of cells 
entering the cell cycle during organ regeneration is due to telomere shortening, independent of 
telomerase per se, but can be rescued by telomere stabilization in mice with critically short 
telomeres.    
 
3.2 Critical telomere shortening at the cellular level blocks cell cycle re-entry of a sub-
population of liver cells in G3 mTERC-/- mice   
A possible explanation for the inhibition of cell cycle re-entry in a sub-population of 
cells in G3 mTERC-/- mice is that telomeres in cells of an organ system are heterogeneous and 
that only cells with critically short, dysfunctional telomeres are inhibited from entering the 
cell cycle. To test this hypothesis, telomere length was analyzed at the single cell level using 
quantitative fluorescence in situ hybridization (qFISH) (120) in combination with BrdU 
staining (Figure 3.2.1A-C). With this approach it is possible to directly compare telomere 
lengths between liver cells participating in organ regeneration (BrdU-positive) and liver cells 
inhibited (BrdU-negative) from cell cycle re-entry.  In mTERC+/+ mice BrdU positive and 
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negative liver cells (120 hrs after PH and continuous labeling with BrdU) showed similar 
mean telomere fluorescence intensities (Figure 3.2.1 D, E and H). As expected, the overall 
telomere fluorescence intensity was lower in G3 mTERC-/- mice compared to mTERC+/+ 
mice. But interestingly within the liver of G3 mTERC-/- the telomere fluorescence intensity 
was significantly weaker in the sub-population of cells inhibited from cell cycle re-entry 
(BrdU negative) compared to the population of proliferating cells (BrdU positive) (Figure 
3.2.1 F, G and H). The observation that the mean telomere fluorescence intensities between 
BrdU positive and BrdU negative cells 120 hrs after PH were similar in mTERC+/+ mice 
indicates that BrdU staining and cell cycle stage did not interfere with hybridization and 
quantification of the telomeric probe at the telomeres. These data gave direct evidence that 
critically short telomeres at the cellular level limit the proliferative capacity of cells within an 
organ system.  
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Figure 3.2.1: Telomere length analysis at cellular level by quantitative fluorescence in situ 
hybridization (qFISH) was combined with BrdU staining (A-C). (A) DAPI counter-staining 
(B) Q-FISH with a telomere specific probe Cy3-OO-(CCCTAA)3.  (C) BrdU staining with 
anti-5-bromo-2’-deoxyuridine monoclonal antibody and FITC-conjugated secondary 
antibody. The liver samples from 120 hrs of continuous BrdU labeling after PH were used to 
measure and compare the telomere fluorescence intensities in BrdU positive and BrdU 
negative cells. In total, the fluorescence intensities of telomere spots were analyzed from 69 
BrdU positive, 54 BrdU negative nuclei from mTERC+/+ (n=5) and 66 BrdU positive and 60 
BrdU negative nuclei from G3 mTERC-/- (n=5) mice.  (D) Telomere fluorescence intensity of 
BrdU positive cells in mTERC+/+ mice (E) BrdU negative cells in mTERC+/+ mice (F) BrdU 
positive cells in G3 mTERC-/- mice (G) BrdU negative cells in G3 mTERC-/-. (H) The mean 
telomere fluorescence intensities of BrdU positive (952.53±144.19) and negative cells 
(957.44±130.57) in mTERC+/+ and BrdU positive (509.65±101.30) and negative cells 
(364.94±116.45) in G3 mTERC-/- mice.  
 
3.3 Non-proliferating cells with critically short telomeres in mTERC-/- are senescent 
          A possible mechanism for inhibition of cell cycle re-entry in a sub-population of cells is 
the induction of cellular senescence, which in primary human cells is induced after 50-70 cell 
doublings, first affecting sub-clones with critically short telomeres of a given cell line in vitro 
(19-21). To directly test whether the non-proliferating cells in G3 mTERC-/- entered 
senescence, SA-β-galactosidase staining (72) was conducted on liver samples at 120 hrs after 
PH to directly compare the percentage of SA-β-galactosidase positive cells with the 
percentage of non-proliferating cells (BrdU negative). This method revealed significantly 
increased rates of senescent cells in G3 mTERC-/- mice compared to mTERC+/+ mice (Figure 
3.3.1A-B).  
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Figure 3.3.1 (A) SA-β-gal staining at pH 6 shows higher number of positive cells in G3 
mTERC-/- (n=5) mice (10.83±3.61%) compared to mTERC+/+ (n=5) mice (2.54±0.7% 
p<0.0001). (B) Representative photographs of SA-β-gal stained liver sections (120 hrs after 
PH) of mTERC+/+ and G3 mTERC-/- mice (magnification bar: 300µm).   
 
Even though SA-β-galactosidase staining is widely used as a marker of senescence it has been 
shown that false positive results occur in vitro in cell cultures exposed to various stresses 
(122). To exclude unspecific non-senescence related SA-β-galactosidase staining a co-
staining combining BrdU staining with SA-β-galactosidase staining was conducted. This co-
staining revealed a strong coincidence of β-gal activity with non-proliferating cells (BrdU-
negative) in G3 mTERC-/- mice. Specifically, only 13±4.84% of the SA-β-galactosidase 
positive cells were BrdU positive, whereas 79±6.2% of the SA-β-galactosidase negative 
fraction of cells showed BrdU incorporation (Figure 3.3.2 A-C).  
 
Figure 3.3.2 Co-localization of SA-β-gal activity in non-proliferating liver cells of G3 
mTERC-/- mice. Representative photographs of (A) SA-β-gal staining (B) BrdU staining with 
anti-BrdU-FITC antibody showing the non proliferative cells are positive to SA-β-gal 
activity. (C) Histogram showing only 13±4.84% of SA-β-gal positive cells are BrdU positive, 
whereas 79±6.2% of the SA-β-gal negative cells are BrdU positive. 
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To directly show that the SA-β-galactosidase positive cells in G3 mTERC-/- mice 
were inhibited from cell cycle re-entry by critically short telomeres a co-staining combining 
SA-β-galactosidase staining with telomeric qFISH was carried out.  As anticipated from the 
above results this analysis revealed significantly weaker telomere fluorescence intensities in 
SA-β-galactosidase positive cells compared to SA-β-galactosidase negative cells in G3 
mTERC-/- mice (Figure 3.3.3 A-E). In contrast, mTERC+/+ mice had no difference in the 
telomere fluorescence intensity comparing SA-β-galactosidase positive and negative cells.  
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Figure 3.3.3 SA-β-gal positive cells have critically short telomeres. Representative 
photograph of (A) SA-β-gal and (B) telomere probe co-staining showing that the fluorescent 
intensity of telomere spots are weaker in SA-β-gal positive cells. (C-E) The frequencies of 
mean telomere fluorescence intensities in nuclei of (top to bottom): (C) SA-β-gal negative 
cells in mTERC+/+, SA-β-gal positive cells in mTERC+/+, (D) SA-β-gal negative cells in G3 
mTERC-/- and SA-β-gal positive cells in mTERC-/-.  (E) The mean telomere fluorescence 
intensities of SA-β-gal negative and positive cells in mTERC+/+ and SA-β-gal negative and 
positive cells in mTERC-/-. In total the fluorescence intensities of telomere spots are analyzed 
from 89 SA-β-gal negative (963.10±130.65) and 46 SA-β-gal positive cells (937.30±135) 
from mTERC+/+ (n=5) and 75 SA-β-gal negative (521.86±100.16) and 65 SA-β-gal positive 
cells (352.13±119.63) from mTERC-/- (n=5) mice. Note that the telomere fluorescence 
intensity in mTERC+/+ mice is similar between SA-β-gal positive and negative cells, 
indicating that SA-β-gal staining did not interfere with telomere probe hybridization and 
measurement. 
 
Therefore, the low prevalence of SA-β-galactosidase positive cells in mTERC+/+ 
mice was independent of telomere shortening possibly resembling the "premature senescence" 
phenotype induced by mitogenic stimulation such as ras-signaling (84). Although an 
interference of SA-β-galactosidase staining or senescence per se with telomere probe 
hybridization and measurement during qFISH remains formally possible, the data showing 
similar telomere fluorescence intensity in SA-β-gal positive and negative liver cells of 
mTERC+/+ mice indicate that such an interference did not occur.   
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3.4 Differentially expressed genes in response to induction of senescence in vivo 
 The Rb- and p53-pathways have been prominently associated with cellular 
senescence (13-16, 66, 68, 79). To test for an activation of these senescence pathways in 
mTERC-/- mice, Affimetrix high density oligonucleotide microarray analysis was carried out 
in duplicate comparing gene expression levels in quiescent liver and at the G1/S transition of 
the cell cycle during liver regeneration (30-36 hrs after PH). This time point was chosen since 
most of the known senescence-pathways are active at this transition point and senescent cells 
can not over come this G1/S checkpoint unless the cell cycle machinery is experimentally 
perturbed (79, 123). We monitored gene expression changes between these two time points 
and compared the differentially regulated genes in mTERC+/+ mice and G3 mTERC-/- mice. 
This experiment identified several differentially expressed genes, 30 genes that were only 
regulated in mTERC+/+ but not in G3 mTERC-/- mice and 76 genes that were only regulated in 
G3 mTERC-/- mice but not in mTERC+/+ mice and 81 genes that were regulated in both 
mTERC+/+ and G3 mTERC-/- mice. Comparison of the genes at quiescence stage between 
mTERC+/+ and G3 mTERC-/- identified only 4 differentially regulated genes in G3mTERC-/- 
mice. The full dataset of this micro-array experiment and the experimental design is 
accessible in MIAME-format online (www.gbf.de/array) under downloads (under 
Satyanarayana et al.: Table1, Table2, and ExperimentalDesign).   
 
Table 3.4.1 Differentially expressed genes at G0-G1/S transition in mTERC+/+ and mTERC-/- 
mice 
 
 
No 
Gene description Gene 
symbol 
∆  
mTE
RC+/+
∆ 
mTE
RC-/-
Gene 
bank 
acc.# 
Stress and acute phase response 
1 Heat shock protein, 86 kDa 1 Hsp86-1 2.83 2.77 J04633 
2 Hypopolysaccharide binding protein Lbp 2.28 2.43 X99347 
3 Inter alpha-trypsin inhibitor, heavy chain 4 Itih4I 2.43 2.62 AF023919 
4 Secretory leukocyte protease inhibitor Slpi 2.13 3.86 AF002719 
5 Serine protease inhibitor 2-2 Spi2-2 4.11 3.92 M64086 
Metabolism/Transport/Surface receptors/Cytoskeleton 
6 Apolipoprotein A-IV Apoa4 14.42 15.35 M64248 
7 Aquaporin 8 Aqp8 -4.29 -2.16 AF018952 
8 Carbonic anhydrase 13  Car13 -6.77 -12.64 AJ006474 
9 Carboxylesterase 1 Ces1 -3.58 -2.95 Y12887 
10 Cd63 antigen Cd63 5.24 6.36 D16432 
11 Cytochrome P-450 Cyp4a10 2.28 2.27 AB01842
1 
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12 Cytochrome P450, 1a2, aromatic compound 
Inducible 
Cyp1a2 -2.39 
 
-2.95 
 
X04283 
13 Cytochrome P450, 2a4 Cyp2a4 -8.75 -11.63 M19319 
14 Cytochrome P450, 2f2 Cyp2f2 -2.91 -3.66 M77497 
15 Cytochrome P450, 4a14 Cyp4a14 2.39 4.41 Y11638 
16 Dynein, cytoplasmic, light chain 1 Dnclc1 5.58 5.50 AF020185 
17 Esterase 1 Es1 -3.48 -4.06 AW22693
9 
18 Fatty acid binding protein 2, intestinal Fabp2 3.07 3.53 M65034 
19 Glutathione S-transferase, theta 1 Gstt1 -2.43 -2.14 X98055 
20 Guanidinoacetate methyltransferase  Gamt -2.60 -3.66 AF010499 
21 Heat shock 70kD protein5(glucose-regulated 
protein) 
Hspa5 2.45 
 
2.16 
 
AJ002387 
22 Hepatic triglyceride lipase Lipc -2.36 -2.81 X58426 
23 Hydroxysteroid 11-beta dehydrogenase 1 Hsd11b1 -2.31 -2.01 X83202 
24 Hydroxysteroid dehydrogenase-5, delta<5>-3-
beta 
Hsd3b5 -4.17 -12.55 L41519 
25 Lipocalin 2 Lcn2 377.41 145.01 X81627 
26 Metallothionein-I Mt1 2.54 2.38 V00835 
27 Metallothionein II Mt2 2.33 2.85 K02236 
28 Nicotinamide N-methyltransferase Nnmt 4.50 3.58 U86108 
29 Niemann Pick type C1 Npc1 -2.91 -2.23 AF003348 
30 Orosomucoid 1 Orm1 2.69 2.62 M27008 
31 Orosomucoid 2 Orm2 10.70 16.56 M12566 
32 Proteaseome (prosome, macropain) 28 subunit, 3 Psme3 2.11 2.58 AB00713
9 
33 Selenium binding protein 1 Selenbp1 -2.33 -3.41 M32032 
34 Serum amyloid A 1 Saa1 16.80 21.86 M13521 
35 Serum amyloid A 2 Saa2 25.28 45.89 U60438 
36 Serum amyloid A 3 Saa3 3.53 7.31 X03505 
37 Serum amyloid P component Sap 8.40 7.21 M23552 
38 Solute carrier family 2 (facilitated glucose 
transporter), member 2 
Slc2a2 -3.03 
 
-2.45 
 
X15684 
39 Thioether S-methyltransferase Temt -18.13 -19.29 M88694 
40 Tubulin, alpha 1 Tuba1 2.13 2.10 M28729 
41 Tubulin, alpha 6 Tuba6 2.53 2.66 M13441 
42 Tubulin, beta2 Tubb2 9.32 14.52 M28739 
43 Tubulin, beta 3 Tubb3 3.14 4.69 AW05025
6 
Cell cycle, DNA damage and apoptosis 
44 B-cell translocation gene 2, anti-proliferative Btg2 5.10 2.13 M64292 
45 Gro1 oncogene Gro1 7.89 8.40 J04596 
46 Growth arrest specific 1 Gas1 -2.43 -2.68 X65128 
47 Histone H1 gene His1a 3.05 2.43 J03482 
48 Leukemia inhibitory factor receptor Lifr -5.39 -6.73 D17444 
49 Nuclear factor, interleukin 3, regulated Nfil3 3.25 2.64 U83148 
Growth, Differentiation & Signal transduction 
50 Activating transcription factor 5  Atf5 2.85 3.73 AB01227
6 
51 Complement component 2  C2 -2.13 -2.38 M57891 
52 Corticosteroid binding globulin Cbg -5.70 -6.68 X70533 
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53 Eukaryotic translation initiation factor 1A Eif1a 3.27 2.28 AF026481 
54 Insulin-like growth factor binding protein 1 Igfbp1 2.69 2.85 X81579 
55 Peroxisome proliferator activated receptor alpha Ppara -2.07 -2.08 X57638 
56 Polymeric immunoglobulin receptor Pigr -3.03 -3.20 AB00148
9 
57 Regulator of G-protein signaling 16 Rgs16 -7.78 -9.71 U94828 
58 RNA binding motif protein 3 Rbm3 2.17 2.89 AB01642
4 
59 Serine protease inhibitor 2, related sequence 1 Spi2-rs1 3.58 3.92 X69832 
60 Sphingosine kinase 2 Sphk2 -7.11 -7.06 AW04734
3 
61 Stimulated by retinoic acid 14 Stra14 -2.36 -2.46 Y07836 
62 Thyroid hormone responsive spot14 Thrsp -5.90 -9.06 X95279 
63 Ubiquitin specific protease 2 Usp2 -3.39 -3.78 AI846522 
Unknown Function 
64 Camello-like 1  Cml1 -2.64 -2.91 AI840501 
65 Sec61, gamma subunit Sec61g 2.23 2.55 U11027 
ESTs 
66 DnaJ(Hsp40)homolog, subfamily B,member11 Est 2.11 2.58 AW12255
1 
67 Homologous to Arginine rich mutated in early 
tumors 
Est 2.85 3.07 AW12236
4 
68 Homologous to isovaleryl coenzyme A 
dehydrogenase 
Est -2.45 
 
-2.66 
 
AW04774
3 
69 Homologous to stearoyl-CoA desaturase Est -3.07 -2.07 M21285 
70 Leucine-rich alpha-2-glycoprotein Est 3.46 3.07 AW23089
1 
71 PLZF gene Est 3.68 11.31 AI553024 
72 Similar to Acetyl-CoA acyltransferase, 3-oxo 
acyl-CoA thiolase A, peroxisomal 
Est -2.81 -2.23 
 
AW01258
8 
73 Similar to prohepcidin Est -2.71 -2.69 AI255961 
74 Similar to thyrotroph embryonic factor Est -5.66 -3.27 AI850638 
75 Un-known gene Est -2.85 -2.58 AI853773 
76 Un-known gene Est -7.26 -10.34 AI266885 
77 Un-known gene Est 2.25 3.14 AA92106
9 
78 Un-known gene Est 2.57 4.00 AI847162 
79 Un-known gene Est 2.17 3.05 AI848235 
80 Un-known gene Est 2.41 2.62 AW12517
8 
81 Un-known gene Est 2.35 2.28 AW04957
0 
 
∆ Fold change, Acc.# Accession number 
 
Table 3.4.2 Differentially expressed genes at G0-G1/S transition only in mTERC+/+ mice 
 
No                            Gene Description    Gene  
  symbol 
    ∆ 
mTER 
Gene bank 
Acc.# 
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C+/+
Stress and acute phase response 
1 Phospholipase A2 Pla2 2.68 AI845798 
2 Stress induced phosphoprotein 1 Stip 1 2.14 U27830 
Metabolism/Transport/Surface receptors/Cytoskeleton 
3 Beta III spectrin Spnb3 -3.27 Af026489 
4 Cytochrome P450 Cyp7b1  Cyp7b1 2.22 U36993 
5 Cytochrome P450, 2b9, phenobarbitol inducible Cyp2b9 -11.96 M21855 
6 Ftty acid synthase Fasn -2.07 X13135 
7 Ia-associated invariant chain Ii -3.43 X00496 
8 Immunophilin FKBP51 FKBP51 2.03 U16959 
9 Peroxisomal/mitochondrial dienoyl-CoA isomerase 
ECH1p 
ECH1p 2.14 Af030343 
10 Proprotein convertase 4 pc4 -23.75 L21221 
11 Sialyltransferase 4A (beta-galactosidase alpha-2,3-
sialytransferase 
Siat4a 2.41 X73523 
12 Squalene epoxidase Sqle 2.10 D42048 
13 Stearoyl-CoA desaturase SCD -2.35 M21285 
Cell cycle, DNA damage and apoptosis 
14 Leukemia-associated gene  Lag 2.04 AI843359 
15 MORF-related gene X  Mrgx 2.73 AB025049 
16 Sirtuin 3 (silent mating type information regulation 2, 
homolog) 3 
sirtuin 3 -2.20 AI849490 
Growth, Differentiation & Signal transduction 
17 CCAAT/enhancer binding protein (C/EBP), alpha Cebpa -2.07 M62362 
18 CCAAT/enhancer-binding protein delta Cebpd 3.25 X61800 
19 Hemoglobin, beta adult major chain Hbb-b1 -2.03 AV003378 
20 Inhibin/activin bC subunit Inhbc 2.17 X90819 
21 Insulin-like growth factor binding protein-2 Igfbp2 -2.58 X81580 
22 Traf and Tnf receptor associated protein Ttrap -3.14 AW228036 
23 TRAM1 TRAM1 2.35 AA763937 
ESTs 
24 Homologous to protocadherin gamma EST 2.50 AA222943 
25 Homologous to UMP-CMP kinase EST 2.13 AI851401 
26 Un-known gene EST 3.89 AI853226 
27 Un-known gene EST 2.75 AW049360 
28 Un-known gene EST 4.63 AA874329 
29 Weakly similar to Gastrulation specific protein G12 EST -2.14 AI844396 
30 Weekly similar to ribosomal protein L11 
methyltransferase 
EST 3.01 AI553401 
 
∆ Fold change, Acc.# Accession number 
 
 
 
Table 3.4.3 Differentially expressed genes at G0-G1/S transition only in G3 mTERC-/- mice 
 
 
No 
 
                             Gene Description 
Gene 
Symbol 
∆ 
mTE
Gene 
Bank 
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RC-/- Acc.# 
Stress and acute phase response 
1 Inter-alpha-inhibitor3  Itih3 2.14 X70393 
2 Orosomucoid 3 Orm3 2.73 S38219 
Metabolism/Transport/Surface receptors/Cytoskeleton 
3 Actin gamma Actg 2.27 M21495 
4 Alpha tubulin isotope M-alpha-2 Tuba2 2.36 M28727 
5 Aminolevulinic acid synthase 2, erythroid Alas2 -2.75 M15268 
6 Arginine vasopressin receptor 1A Avpr1a 2.01 D49730 
7 Calcium channel gamma 6 Cacng6 2.11 Ai849587 
8 Carbonic anhydrase 14 Car14 -2.31 AB005450 
9 Carbonic anhydrase 5a, mitochondrial Car5a -2.20 X51971 
10 Cathepsin F Ctsf -2.16 AJ131851 
11 Cytochrome p450, 2b10, phenobarbitol inducible type b Cyp2b10 12.47 M21856 
12 Cytochrome P450, 7a1 Cyp7a1 -8.17 L23754 
13 Dopa decarboxylase Ddc 3.89 AF071068 
14 Ferridoxin 1 Fdx1 -2.06 L29123 
15 Flotillin 1 Flot1 2.04 U90435 
16 Frizzled homolog4 Fzd4 -2.23 Aw122897 
17 Glutathione-S-transferase mu-3 Gstm3 -2.36 J03953 
18 Glycerol kinase Gyk 2.25 U48403 
19 Hydroxysteroid dehydrogenase-2, delta<5>-3-beta Hsd3b2 -2.68 M75886 
20 Ornithine transcarbamylase Otc -2.36 X07092 
21 Pyruvate dehydrogenase kinase like protein Pdk4 8.69 Aj001418 
22 Sarcosine dehydrogenase Sardh -2.53 AI839995 
23 Serum/glucocorticoid regulated kinase Sgk 2.27 AW046181 
24 Solute carrier family 35 (UDP-galactose transporter), 
member 2 
Slc35a2 2.55 D87990 
25 Sterol-C5-desaturase Sc5d -2.41 AB016248 
26 Tropomyosin isoform 1 Tpm1 2.30 M22479 
Circadian rhythms 
27 Aryl hydrocarbon receptor nuclear translocator like Arntl 7.16 Ab014494 
Cell cycle, DNA damage and apoptosis 
28 Carnitine acetyl transferase Crat 2.23 X85983 
29 Cyclin dependent kinase inhibitor 1A, p21 Cdkn1a 8.63 Aw048937 
30 Fas associated factor 1 Faf1 -4.62 U39643 
31 Growth arrest and DNA damage inducible Gadd45g 4.38 Af055638 
32 Krupple like factor 4 Klf4 4.03 U20344 
33 Neighbor of A-kinase anchoring protein-95 Nakap95 -2.01 Ab028921 
34 NIMA (Nerve in mitosis gene-a) related expressed 
kinase-6 
Nek6 2.38 Ai846534 
35 Nucleobindin2 Nucb2 17.51 Aj222586 
36 P87 Wee1 kinase Wee1 -6.36 D30743 
37 Polo-like kinase Plk 13.74 Av305987 
38 Protein kinase inhibitor p58 Prkri 2.95 U28423 
39 Ring finger protein 4 Rnf4 -2.10 Ai844517 
40 Sarcosine oxidase Pso -2.48 U94700 
41 Senescence marker protein 30 Smp-30 2.11 U28937 
Growth, Differentiation & Signal transduction 
42 Cytokine inducible SH-2 containing protein-3 Cish3 4.56 Av374868 
43 Ectonucleotide pyrophosphatase/phosphodiesterase 2 Enpp2 -3.03 AW122933 
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44 Ets varient gene 6 (Tel oncogene) Etv6 2.53 A1845538 
45 Gamma-aminobutyric acid (GABA(A)) receptor-
associated protein-like 1  
Gabarapl1 -2.10 AF180518 
46 Growth differentiation factor 5 Gdf5 -3.73 U08337 
47 Growth factor receptor bound protein-2-associated 
protein-1 
Gab1 -2.22 Ai046826 
48 Kidney expressed gene 1 Keg1 -3.23 Ab028071 
49 LPS-induced TN factor  Litaf 2.16 AI852632 
50 Lymphocyte antigen-6 complex Ly6d 3.46 X63782 
51 Neural precursor cell expressed, 
developmentally down-regulated gene 4b  
Nedd4b 2.25 AI840868 
52 N-myc downstream regulated like Ndrl 2.03 U52073 
53 Nuclear factor I Nfix -2.08 Y07688 
54 Pou domain class3, transcription factor1 Pou3f1 -7.52 X56959 
55 Pre-B-cell colony-enhancing factor Pbef -2.01 AI852144 
56 Prolactin receptor related sequence 1 Prlr-rs1 -2.36 M22957 
57 Protein tyrosine kinase 6 Ptk6 -7.73 U16805 
58 Ras homolog N (RhoN) Arhn 2.57 Af016482 
59 Retinoic acid early transcript gamma Raet1c -2.89 D64162 
60 Ribosomal protein L22  Rpl22 2.46 AK008915 
61 Ribosomal protein L30 Rpl30 2.07 K02928 
62 S100 calcium binding protein A10 (calpactin) S100a10 3.27 M16465 
63 S100 calcium binding protein A8 (calgranulin A) S100a8 5.03 M83218 
64 Thymidine kinase Tk -2.64 X60980 
65 Zeta chain (TCR) associated protein kinase Zap70 -2.51 Ai386093 
Unknown Function 
66 Bri3, Brain protein I 3  Bri3 -2.23 X61454 
67 Glutathione S-transferase, mu 6 Gstm6 -2.25 AI326397 
68 SEC61, alpha subunit Sec61a 2.16 AI838624 
69 Sulfotransferase-related protein Sult-x1 -2.89 AF026074 
ESTs 
70 Homologous to alpha-1-antiproteinase precursor Est -2.50 AI645694 
71 Homologous to MCM10 Est -3.39 AA867646 
72 Protein disulfide isomerase-related protein Est 2.16 AW045202 
73 Similar to integral membrane transport protein UST5r Est -3.20 AI647632 
74 Un-known gene Est 2.69 AI849939 
75 Un-known gene Est 2.95 AW227650 
76 Un-known gene Est 2.36 AW046006 
 
∆ Fold change, Acc.# Accession number 
 
Table 3.4.4 Differentially expressed genes at quiescence stage only in G3 mTERC-/- mice 
compared with mTERC+/+ mice 
 
 
No 
                     Gene description Gene 
symbol 
∆  
mTERC+/+ 
Vs 
mTERC-/- 
0 h 
Gene 
bank 
acc.# 
1 Cytochrome P450, 2b9, phenobarbitol inducible  Cyp2b9 -15.24 M21855 
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2 Cytochrome p450, 2b10, phenobarbitol inducible 
type b 
Cyp2b1
0 
-2.30 M21856 
3 Epidermal growth factor Egfr 2.23 L06864 
4 Retinoic acid early transcript gamma Raet1c 2.16 D64162 
 
∆ Fold change, Acc.# Accession number 
 
From the differentially regulated genes in the micro-array experiments comparing 
resting liver and regenerating liver at 30-36 hours after PH between mTERC+/+ mice and G3 
mTERC-/- mice 8 target genes, which have a role in cell cycle regulation, were chosen and 
their differential expression was confirmed by rt-PCR (Table 3.4.5) with specific primers to 
each gene. The gene list include 4 downstream targets of p53 (p21, plk, Gadd45g, and KLF-4) 
which were all up-regulated in G3 mTERC-/- mice, two of these genes (p21 and Gadd45g) 
have been previously related to replicative senescence and DNA-damage response that leads 
to G1/S arrest (124, 125).  
 
Table 3.4.5 Differentially expressed cell cycle regulating genes at G0-G1/S transition in G3 
mTERC-/- mice compared with mTERC+/+ confirmed by real time quantitative PCR 
 
N
o 
    Gene description Symbol ∆ 
RT-
PCR 
              Function Gene bank 
1 Cyclin dependent 
kinase inhibitor 1A, 
p21 
Cdkn1a 6.02 Senescence, DNA damage 
response, cell cycle 
regulation           
Aw048937 
2 Fas associated factor 1 Faf1 -4.08 Apoptosis U39643 
3 Growth arrest and 
DNA damage inducible 
Gadd45 5.09 DNA damage response, Cell 
cycle arrest 
Af055638 
4 Krupple like factor 4 Klf4 5.77 DNA damage response U20344 
5 Nucleobindin2 Nucb2 12.9 Cell cycle regulation, growth 
arrest 
Aj222586 
6 P87 Wee1 kinase Wee1 -5.93 DNA damage response, cell 
cycle regulation 
D30743 
7 Polo-like kinase Plk 8.63 DNA damage response, cell 
cycle regulation 
Av305987 
8 Protein kinase inhibitor 
p58
Prkri 3.60 Growth regulation U28423 
 
∆ – fold change of gene expression  
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Table 3.4.6 Differential expression of eight target genes are confirmed by RT-PCR with 
specific primers and their comparative expression levels with microarray analysis 
 
N
o. 
   Gene ∆ 
RT-
PCR 
∆ 
Micro
array 
1 Nucb2 12.90 17.51 
2 Prkri 3.60 2.95 
3 Plk 8.63 13.74 
4 P21 6.02 8.63 
5 Gadd45g 5.09 4.38 
6 Faf1 -4.08 -4.62 
7 Wee1 -5.93 -6.36 
8 Klf4 5.77 4.03 
 
∆-Fold change 
 
 
3.5 Cells with sufficient telomere reserves in G3 mTERC-/- mice compensate for 
impaired organ regeneration by an additional round of replication  
Synchronized liver regeneration in response to two-thirds partial hepatectomy (PH) 
takes approximately one and half rounds of replication to restore organ mass within one week 
after PH (101, 102). In the C57BL/6 mouse-strain used in our studies the first peak stage of S-
phase was observed at 48 hours and was followed by a smaller second peak at 96 hours after 
PH (Figure 3.5.1). We evaluated S-phase onset and progression in response to PH in 
mTERC+/+ mice and G3 mTERC-/- mice by BrdU pulse-labeling (Figure 3.5.1A-E). In 
response to PH the timing of the onset and the peak stages of S-phase were superimposable in 
mTERC+/+ and G3 mTERC-/- mice. Nevertheless, the percentage of liver cells participating in 
the first round of replication was significantly lower in G3 mTERC-/- mice compared to 
mTERC+/+ mice (Figure 3.5.1 C, D, E).  In contrast, a significantly higher fraction of liver 
cells entered a second round of replication in G3 mTERC-/- mice compared to mTERC+/+ mice 
(Figure 3.5.1 D, E).   
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Figure 3.5.1 (A-D) Representative photographs of BrdU staining pattern at the two peak 
stages of S-phase in mTERC+/+ and G3 mTERC-/- mice (Magnification bar: 150 µm). (E) 
Percentage of BrdU positive cells at different time points after PH in mTERC+/+ and (G3) 
mTERC-/- mice as determined by 2-hours of BrdU pulse labeling.  mTERC+/+ mice show a 
higher percentage of BrdU positive cells (47.03±6.33%, n=5) at the first peak stage of S-phase 
(48hrs after PH) compared to G3 mTERC-/- mice (32.31±6.65%, n=5, p<0.0001). In contrast, 
at the second peak stage of S-phase (96h after PH) G3 mTERC-/- mice show higher 
percentage of BrdU-positive cells (21.58±4.24%, n=5) compared to mTERC+/+ mice 
(12.66±1.69%, n=5, p<0.0001).  
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To test whether impaired S-phase entry would impact on organ regeneration and 
whether the elevated second round of replication could compensate for impaired regeneration 
we followed the relative liver weight (liver weight/total body weight) of mTERC+/+ and G3 
mTERC-/- mice at different time points after PH. In parallel to the time course of S-phase, the 
liver weight of G3 mTERC-/- mice compared to mTERC+/+ mice was significantly decreased 
after the first round of replication, 72 hours after PH (relative liver weight: 2.27% in G3 
mTERC-/- mice compared to 2.74% in mTERC+/+ mice, p=0.001). In agreement with our 
hypothesis that liver cells with sufficient telomere reserves accomplished organ regeneration 
in G3 mTERC-/- mice by entering a second round of replication the liver weight was 
normalized in G3 mTERC-/- mice after the second round of replication, 120 hours after PH. 
Similarly, the difference in total number of BrdU labeled cells (after long-term labeling) 
between G3 mTERC-/- and mTERC+/+ mice (Figure 3.1.1A) was significantly reduced after 
the second round of replication as compared to first round of replication (-4.69%, p=0.0274). 
 
3.6 Inhibition of S-phase entry, impaired G2/M progression, and additional round of cell 
division in regenerating liver of G3 mTERC-/- mice  
Together, our data indicated that impaired liver regeneration was due to inhibition of 
cell cycle re-entry in a sub-population of cells with critically short telomeres in G3 mTERC-/- 
mice but was compensated for by an additional round of replication by liver cells with 
sufficient telomere reserves capable of proliferation. An alternative explanation was that a 
sub-population of resting liver cells in G3 mTERC-/- mice was not in the G0 stage but arrested 
in G2/M and was released from this block to exit mitosis and therefore re-entered the cell 
cycle at a delayed time-point after PH. To test this possibility cell cycle analysis was carried 
out by flow cytometry on resting and regenerating livers of mTERC+/+ and G3 mTERC-/- mice 
(Figure 3.6.2).   
 
Since in mouse liver a relatively high percentage of cells are bi-nucleated this analysis 
was carried out on cell nuclei, although cytospins on liver cells did not show a difference in 
the percentage of mono-nuclear (22.51±7.77 vs 25.66±3.83, p=0.2645) as well as bi-nucleated 
(76.99±8.90 vs 74.32±3.82, p=0.395) cells in mTERC+/+ and G3 mTERC-/- mice (Figure 3.6.1 
A-C).  
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Figure 3.6.1 The initial composition of the liver is similar in G3 mTERC-/- and mTERC+/+ 
mice. (A-B) Representative H&E stained photographs of isolated liver cells from G3 mTERC-
/- and mTERC+/+ at quiescent stage (Blue arrows indicate mono-nuclear cells and black arrows 
indicate bi-nuclear cells). (C) Histogram showing the percentage of mono-nuclear 
(22.51±7.77 vs 25.66±3.83, p=0.2645) as well as bi-nucleated (76.99±8.90 vs 74.32±3.82, 
p=0.395) cells in mTERC+/+ and G3 mTERC-/- mice. 
 
In line with previous reports of flow cytometry on liver cell nuclei of several strains of 
mice (126, 127) our study revealed that beside a cell population with a 2n DNA content a 
proportion of resting liver cell nuclei had 4n DNA content. Cell cycle analysis of resting liver 
cell nuclei from G3 mTERC-/- and mTERC+/+ mice revealed a similar distribution of nuclei 
with 2n and 4n DNA content in both groups (Table 3.6.1, Figure 3.6.2 A-B). In line with the 
BrdU-staining data the FACS analysis revealed that 48 hours after PH the overall number of 
cells in S-phase was significantly lower in G3mTERC-/- compared to mTERC+/+ mice (Table 
3.61, Figure 3.6.2 C-D, top panel). Interestingly, the suppression of S-phase entry in G3 
 67
  Results  
mTERC-/- mice affected cells with 2n, 4n, and higher DNA content. Although it can not be 
excluded that some of the 4n and 8n cells were arrested at G2/M stage of the cell cycle, the 
inhibition of S-phase entry from 2n cells indicated that suppressed S-phase entry in G3 
mTERC-/- was at least in part due to a pre-S-phase arrest.  
 
As anticipated from the BrdU staining results (Figure 3.5.1) FACS analysis at 96 
hours after PH revealed a higher percentage of liver cells in S-phase in G3 mTERC-/- 
compared mTERC+/+ mice (Table 3.6.1, Figure 3.6.2 C-D, bottom panel). The fact, that this 
S-phase entry predominantly derived from cells with 4n and 8n DNA content suggested that 
the second peak of S-phase in G3 mTERC-/- mice did not result from 4n cells overcoming a 
G2/M-block to re-enter S-phase from a 2n-stage after completion of mitosis.  
 
In addition to the above data on S-phase entry, the FACS analysis revealed an 
accumulation of cells with higher DNA content in G3mTERC-/- compared to mTERC+/+ mice 
in the time course of liver regeneration following PH. These data are in line with previous 
reports of an impaired G2/M progression of regenerating liver cells in mTERC-/- mice (98). 
Cell cycle analysis 21 days after PH revealed again an almost similar ploidy distribution in 
mTERC+/+ and G3 mTERC-/- mice (Figure 3.6.2 E-F) indicating that impaired G2/M 
progression in G3 mTERC-/- was either temporary or associated with decreased cell survival 
over time. It appears that the level of telomere dysfunction determines the proliferative fate of 
the cell and the activation of cell cycle checkpoints (Figure 3.6.3). 
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Figure 3.6.2 (A-F) Representative photographs of one of the five independent flow 
cytometric analysis of liver nuclei at each time point from mTERC+/+ and G3 mTERC-/- mice. 
(A) & (B) Ploidy distribution of cell nuclei from quiescent liver showing an almost similar 
composition of 2n and 4n nuclei in mTERC+/+ and G3 mTERC-/- mice. (C) & (D) Cell cycle 
profile of liver nuclei 48 hrs after PH (top panel) shows a significantly lower number of 2n 
(p=0.0031) and 4n (p=0.0219) nuclei are positive to BrdU in G3 mTERC-/- compared to 
mTERC+/+ indicating that G1/S progression was inhibited in a subset of liver cells in G3 
mTERC-/- mice. In contrast, an increased number of 2n (p=0.0516), 4n (p=0.0005) and 8n 
(p=0.0074) nuclei incorporate BrdU at 96 hrs (lower panel) after PH in G3 mTERC-/- 
compared to mTERC+/+ indicating that a higher number of liver cells in G3 mTERC-/- mice 
entered a second round of replication.  Beside these differences in BrdU incorporation there is 
an accumulation of cells with higher DNA content in G3 mTERC-/- mice during the time 
course of liver regeneration indicating that G2/M progression was impaired. (E) & (F) Ploidy 
distribution of liver nuclei 21 days after PH showing again an almost similar DNA content in 
mTERC+/+ and mTERC-/- : 2n (p=0.0683), 4n (p=0.9831) and 8n (p=0.0641) indicating partial 
rescue of G2/M arrest in the course of time. 
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Table 3.6.1 Ploidy distribution and cell cycle profile of quiescent and proliferating liver cells 
at the indicated time points after PH in mTERC+/+ and G3 mTERC-/- as analysed by flow 
cytometry 
 
 
Time 2N 4N 8N 2N S-phase 4N S-phase 8N S-phase 
mTERC+/+  
0 hrs 
62.37±6.06 37.6±6.03 --- --- --- --- 
G3 mTERC-/-
0 hrs 
58.94±4.88 41.09±4.93 --- --- --- --- 
mTERC+/+  
48 hrs after PH 
22.15±11.34 26.75±7.53 9.62±3.3 11.93±5.73 21.3±10.6 8.15±3.33 
G3 mTERC-/- 
48 hrs after PH 
23.42±9.26 44.76±11.12 17±7.31 1.76±0.84 8.15±1.47 4.73±1.34 
mTERC+/+  
96 hrs after PH 
43.18±17.25 40.87±13.46 10.98±7.77 1.58±0.83 1.49±1.13 1.36±1.13 
G3 mTERC-/- 
96 hrs after PH 
20.14±6.42 43.26±8.68 25.46±9.86 2.84±1.02 4.41±0.62 4.05±1.29 
mTERC+/+  
21 d after PH 
49.93±2.64 42.97±2.79 6.24±1.33 --- --- --- 
G3 mTERC-/-  
21 d after PH 
42.89±0.72 42.92±1.68 14.43±2.77 --- --- --- 
 
3.7 Apoptosis does not account for the differences in the regenerative response between 
mTERC+/+ and G3 mTERC-/-
To analyze the role of other factors than impaired cell cycle re-entry that could 
explain the decreased rate of proliferation in G3 mTERC-/- mice, we evaluated apoptosis in 
this system. Apoptosis has been linked to impaired organ regeneration of highly self-renewing 
organs in mTERC-/- mice (94) and is induced by telomere shortening in clonally regenerating 
hepatocytes in the setting of acute liver failure (98). We assessed the possible impact of 
apoptosis in our experimental system using the TUNEL assay. Following PH, TUNEL 
staining showed very low but similar rates of apoptosis in the liver of mTERC+/+ and G3 
mTERC-/- mice (Figure 3.7.1) suggesting that this process did not account for the differences 
in regenerative response.  Given that apoptosis is predominantly present in the setting of 
telomere shortening coupled with extensive regenerative pressure in mTERC-/- mice (94, 98) 
it seems possible that limited apoptotic response to PH was indicative of the more moderate 
regenerative stress in this setting. 
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Figure 3.7.1 Impaired organ regeneration induced by telomere shortening correlates to 
cellular senescence but not to apoptosis. (A-B) Representative photographs of TUNEL 
staining on liver sections of mTERC+/+ and G3 mTERC-/- mice at 120 hours after PH (arrows 
indicate the apoptotic cells, magnification bar: 100µm). (C) Time-course changes of the 
TUNEL index in mTERC+/+ and G3 mTERC-/- mice following 70% PH.  The TUNEL index 
per 100 cells is similar in both groups.  
 
3.8 Mitogenic responses are not disrupted by telomere shortening and are essential to 
reveal senescence phenotype in mTERC-/- mice           
          Initial mitogen responses such as the production of growth factors and cytokines are 
necessary for cell cycle re-entry and could be affected by telomere shortening. One of the 
prominent players in priming the liver cells to re-enter the cell cycle is IL-6 which after PH 
reaches peak levels 6-9 hours after operation (128, 129).  Induction and peak levels of IL-6 in 
response to PH were similar in mTERC+/+ and G3 mTERC-/- mice (Figure 3.8.1) indicating 
that other factors than the initial mitogen response inhibited cell cycle re-entry in liver cells 
with critical short telomeres. These data indicate that inhibition of cell cycle re-entry of a 
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fraction of liver cells during liver regeneration in G3 mTERC-/- mice is linked to cellular 
senescence induced by critical telomere shortening rather than impaired mitogenic responses 
or activation of apoptosis.   
 
Figure 3.8.1 IL-6 serum levels in mTERC+/+ and G3 mTERC-/- mice show no difference in 
the induction and at peak stage in response to PH.  
 
To test whether mitogen-stimulation would alter the replicative senescence phenotypes 
induced by telomere shortening, we monitored SA-β-Gal activity in quiescent liver and liver 
stimulated to divide in mTERC-/- and mTERC+/+ mice. We used mTERC-/- mice of the first 
generation (G1), which lack telomerase activity but have long telomere reserves and no 
apparent phenotype (93), as well as G3 mTERC-/- mice, which have critically short telomeres 
(Figure 3.8.2A-D). The quiescent livers has very little mitotic activity with over 95% of the 
cells in the G0-stage of the cell cycle, but in response to PH over 90% of liver cells participate 
in organ regeneration and restore organ mass within 1 week (101, 102).   
 
As described above there was an overall higher prevalence of β-Gal positive liver cells 
in G3 mTERC-/- mice harboring critically short telomeres compared to mTERC+/+ mice (Figure 
3.3.1). The increased incidence of SA-β-Gal positive cells in G3 mTERC-/- mice was mitogen 
dependent showing a strong increase after PH (Figure 3.8.2 A and D). In contrast mTERC+/+ 
and G1 mTERC-/- mice showed only a slight increase in β-Gal positive cells (Figure 3.8.2 A-
C) indicating that induction of SA-β-Gal activity in vivo depends on both telomere shortening 
and mitogen stimulation. The increase of β-Gal positive liver cells in G3 mTERC-/- mice after 
PH followed increased serum levels of IL-6 - the prominent mitogen regulating liver cell cycle 
re-entry in response to organ damage- and there was no difference in the mitogenic response 
between mTERC+/+ and G3 mTERC-/- mice (Figure 3.8.1).  
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Figure 3.8.2 The prevalence of SA-β-Gal staining in response to telomere shortening in vivo 
is mitogen dependent. (A) Histogram of the percentage of SA-β-gal positive cells in quiescent 
and regenerating liver of mTERC+/+, G1 mTERC-/- and G3 mTERC-/- mice showing a 
significant increase of β-gal positive cells in G3 mTERC-/- liver after PH but not in mTERC+/+ 
liver. Note: SAβ-gal staining was analysed only on quiescent livers and 36 hrs after PH for 
G1 mTERC-/- which is comparable with mTERC+/+ (B-D) Representative photographs of β-
gal staining on liver samples from mTERC+/+, G1 mTERC-/- and G3 mTERC-/- at quiescence 
stage and 36 hrs after PH. 
 
 
3.9 mTERC-/- have critically short telomeres and further telomere shortening in the 
subsequent cell division is not necessary to reveal increased senescence phenotype 
Telomere length analysis by q-FISH showed the prevalence of critically shorter 
telomeres in G3 mTERC-/- compared to mTERC+/+ (Figure3.9.1 A-D). To test whether mitogen 
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stimulation itself is responsible for the increased incidence of senescence phenotypes or 
whether further telomere shortening in the subsequent cell division in response to mitogen 
stimulation lead to this phenomenon, we have analysed the S phase activity by two hours of 
BrdU pulse labeling in mTERC+/+ and G3 mTERC-/-. Analysis of S-phase activity showed 
almost zero activity at 36 hrs but a sharp peak at 48 hrs after PH (Figure 3.9.1E-G) indicating 
that the senescence phenotypes in G3 mTERC-/- liver, which became detectable at 36 hour 
after PH (Figure 3.8.1), were independent of further telomere attrition induced by an additional 
round of cell division. 
 
 
 
 
Figure 3.9.1 (A-B) Representive photographs of quantitative fluorescence in situ 
hybridization (Q-FISH) on inter phase nuclei of liver cells from mTERC+/+ and G3 mTERC-/- 
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mice hybridized with a telomere specific probe Cy3-OO-(CCCTAA)3. (C-D) Histogram on 
the distribution of mean telomere fluorescence intensities in nuclei of liver cells from G3 
mTERC-/- mice (n=3) and mTERC+/+ mice (n=3) showing a significantly reduced overall 
mean in G3 mTERC-/- mice compared to mTERC+/+ mice (565±83.17 Vs 1027±135.23, 
p<0.0001). (E-F) Representative photographs of BrdU staining pattern at the onset of S-phase 
(36 hrs after PH) in mTERC+/+ and G3 mTERC-/- mice (Magnification bar: 150 µm). (G) 
Percentage of BrdU positive cells at 36 hrs (2.3±1.08% Vs 1.75±0.77%) and 48 hrs 
(44.03±6.33% Vs 32.31±6.65%) after PH in mTERC+/+ and G3 mTERC-/- mice as determined 
by 2hrs of BrdU pulse labeling. 
 
 
3.10 The in vitro phenotype of replicative senescence induced by telomere shortening is 
dependent on mitogen stimulation 
The modulations of senescence phenotype in response to mitogen stimulation in vivo 
lead us to explore this process further in detail. To analyze whether the senescence phenotype 
and signaling induced by telomere shortening is constitutively operative at the same level or 
amplified by mitogenic stimuli we explored this phenomenon in human fibroblast cultures 
using 3 different cell lines IMR90 (Human fetal lung fibroblasts), WI38 (human embryo lung 
fibroblasts) and HK-1 (human adult fibroblasts) (130-132).  Serial passaging of primary human 
fibroblasts leads to telomere shortening after each round of cell division and after 60-80 PD’s 
they enter replicative senescence due to critical telomere shortening. As described in previous 
studies telomeres were significantly shorter in late passage cells as compared to early passage 
(Figure 3.10.1) (130-132). 
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Figure 3.10.1 The telomere restriction fragment (TRF) length was determined from early, late 
and hTERT IMR90 and HK1 cells. Representative In-gel southern blotting photograph, 1.Late 
passage (PD55) IMR90, 2. Early passage IMR90 (PD30) 3. hTERT-IMR90 (PD68) 4. Late 
passage HK1 (PD60) 5. Early passage HK1 (PD9) 6. hTERT-HK1 (PD90). The mean TRF 
length is significantly shorter in  late passage IMR90 (5.7 kb) compared with early passage 
(8.5 kb) or hTERT-IMR90 (7.8 kb). The mean TRF length is significantly shorter in  late 
passage HK1 (4.8 kb) compared with early passage (7.6 kb) or hTERT-HK1 cells (9.2 kb).  
 
Decreasing cell proliferation at the onset of senescence correlated with an increasing 
prevalence of the markers of cellular senescence: 1. SA-β-Gal activity at pH6 and 2. 
Senescence cell morphology (flattened, irregular cells with enlarged cytoplasm). Consistent 
with previous studies the percentage of cells being positive for both markers reached >60% in 
late passage cells whereas it was <20% at early passage (Figure 3.10.2). To test whether these 
markers of replicative senescence were modulated by altered mitogen stimulus their prevalence 
was quantitated 1. under serial passage, 2. after serum starvation (0.1% FBS for 120 hrs), and 
3. after re-stimulation (10% FBS for 24 hrs) in early and late passage cells. Interestingly these 
experiments revealed that the increase in the percentage of cells showing a senescence-
morphology or positive β-Gal-staining at late passage was strongly dependent on serum 
stimulation but almost completely disappeared in response to serum starvation (Figure 
3.10.2A-I). The diminution of senescence markers in late passage cultures was detectable as 
early as 48 hrs after serum starvation and re-appeared 24 hrs after serum-stimulation.   
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Figure 3.10.2 The phenotype of replicative senescence of primary human fibroblasts is 
mitogen dependent. (A) Representative photographs of IMR90 cells at early passage, late 
passage at the indicated culture conditions. (B, C) Histogram showing the percentage of cells 
with senescent morphology (B) and the percentage of SA-β-gal positive cells (C) in early 
(PD30) and late (PD55) passage IMR90 cells under serial passage in 10% FBS, after serum 
starvation in 0.1% FBS for 120 hrs, and after serum re-stimulation with 10% FBS for 24 hrs. 
The senescent morphology index and the number of SA-β-gal positive cells for early passage 
IMR90 cells are low under all culture conditions.  In contrast, late passage IMR90 show a high 
senescence morphology (75.36±6.14%)  index and a high percentage of SA-β-gal positive cells 
(78.34±7.62%) under serial passage, a significant diminution of senescence morphology 
(23.43±3.29%, p<0.0001) and -β-gal activity  (19.29±3.89%, p<0.0001) in response to serum 
starvation and a significant re-appearance of senescence morphology (72.9±8.17%, p<0.0001) 
and SA-β-gal activity (67.58±8.86%, p<0.0001) in response to serum re-stimulation. (D) 
Representative photographs of early (PD12) and late (PD62) passage WI38 cells (PD75). (E, 
F) Histograms indicating the percentage of WI38 cells showing senescent morphology (E) and 
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SA-β-gal activity (F) in early (PD12) and late passage (PD62) under serial passage in 10% 
FBS, in response to serum starvation in 0.1% FBS for 120 hrs, and in response to serum-re-
stimulation with 10% FBS for 24 hrs. Under serial passage late passage of WI38 cells show 
high rates of senescent morphology (85.62±9.69%) and SA-β-gal activity (89.8±8.16%). Both 
markers are declined in response to serum starvation (44.27±5.52% for senescence 
morphology, p<0.0001, and 43.2±6.56% for SA-β-gal activity, p<0.0001), but re-appeared in 
response to serum re-stimulation (68.06±8.19% for senescence morphology, p<0.0001, and 
79.69±9.05% for SA-β-gal activity, p<0.0001). (G) Representative photographs of early (PD9) 
and late passage (PD60) HK1 cells under different culture conditions. (H-I) Histograms 
indicating the percentage of HK1 cells showing senescent morphology (H) or SA-β-gal 
activity (I) at early (PD9) and late passage (PD60) under serial passage in 10% FBS, in 
response to serum starvation in 01% FBS for 120 hrs, and in response to serum re-stimulation 
in 10% FBS. The early passage cells did not show any signs of senescence. Under serial 
passage late passage HK1 cells show high rates of senescent morphology (61.73±5.27%) and 
SA-β-gal activity (68.93±6.11%). Both markers are declined in response to serum starvation 
(15.98±4.47% for senescence morphology, p<0.0001, and 19.89±3.42% for SA-β-gal activity, 
p<0.0001), but re-appeared in response to serum re-stimulation (55.76±6.73% for senescence 
morphology, p<0.0001, and 62.68±5.59% for SA-β-gal activity, p<0.0001). 
 
To ensure that the phenotypes of senescence in late passage fibroblasts were induced 
by telomere shortening we performed an identical experiment on all 3 cell lines which had 
bypassed the replicative senescence by hTERT expression. The immortalization of WI38 by 
hTERT expression has been documented in previous studies (132), similarly hTERT 
expression is sufficient to immortalize HK-1 cells (S. Zimmermann and U. Martens, 
unpublished). There is some conflict on immortalization of IMR90 cells, however, in our 
laboratory conditions we have successfully established IMR90 cells that clearly by-passed the 
replicative senescence limit upon hTERT-over-expression (the cells were followed until 
PD115), which is in line with observations from other groups  (133). It has been reported that 
even though TERT-expression elongates the lifespan of IMR90 cells they still reach a 
telomere-independent senescent arrest at very late passage (133). We can not exclude that such 
telomere independent factors impact on our in vitro data on IMR90 cells. However, the use of 
3 different cell lines favors that our experiments are in fact relevant for replicative senescence 
induced by telomere shortening, which can be bypassed by hTERT expression.  
 
Two of the three cell lines were tested and both of them showed telomere shortening 
upon serial passaging and both the cell lines showed telomere stabilization upon hTERT-
expression (Figure 3.10.1) In all three cell lines there was no detectable senescence-
morphology or β-Gal-staining at late passage independent of the culture conditions (Figure 
3.10.3A-F).  Similarly, simian virus T-antigen (SV40-T-Ag) expression, which blocks both the 
Rb and p53 pathways, which govern the senescence checkpoint (134), prevented induction of 
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senescence morphology and β-Gal activity in late passage IMR90 cells (Figure 3.10.3 A and 
D). Together, these data indicated that the classical senescence phenotype (induced by 
telomere shortening and bypassed by hTERT or SV40-T-Ag expression) in primary human 
cells can be modulated by altered mitogenic stimulation.  
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Figure 3.10.3 (A) Representative photographs of hTERT expressing IMR90 cells at late 
passage (PD68), and SV40-T-Ag expressing IMR90 cells at late passage (PD65) showing no 
signs of either senescence morphology or SA-β-gal (B-C) Representative photographs of 
hTERT expressing WI38 cells at late passage (PD75), and hTERT expressing HK1 cells at 
late passage (PD90) showing no signs of either senescence morphology or SA-β-gal (D) 
Histogram showing the percentage of SA-β-gal positive cells in late passage IMR90 cells 
expressing SV-40 T-antigen (PD65) or hTERT (PD68) showing no senescence phenotype 
irrespective of the culture conditions. (E) Histogram showing absence of SA-β-gal positive 
cells in late passage (PD75) of hTERT-expressing WI38 cells in response to three different 
culture conditions. (F) Histogram showing absence of SA-β-gal positive cells in late passage 
(PD90) of hTERT-expressing HK1 cells at different culture conditions.   
 
To rule out the possibility that further telomere shortening in the subsequent cell 
division might be the cause for this increased senescence phenotype in response to mitogenic 
stimulation we analyzed S-phase activity in IMR90 and HK1 cells. Early passage cells showed 
S-phase labeling under serial passage and resumption of replication 12-24 hrs after serum 
stimulation of serum starved cultures. In contrast, the late passage fibroblasts did not show any 
significant S-phase activity under serial passage or after serum stimulation of serum starved 
cultures (Figure 3.10.4, Table 3.10.1). These data excluded the possibility that the re-
appearance of senescence phenotypes in response to serum stimulation of late passage human 
fibroblast cultures was due to further telomere shortening in subsequent cell division.  
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Figure 3.10.4 Impaired cell cycle activity and accumulation of cells in G1 stage of the cell 
cycle in late passage. Representative photographs of one of the three independent flow 
cytometric analysis of early and late passage IMR90 cells at the indicated culture condition. 
About 90% of the late passage cells accumulated in G1 phase of the cell cycle even after 24 
hrs of serum stimulation.  
 
 
Table 3.10.1 Cell cycle profile on early and late passage IMR90 and HK1 cells at the 
indicated time point and culture condition 
 
 
Culture 
condition 
IMR 90 Early passage (PD30) 
 
G1               S             G2/M 
IMR 90 Late passage (PD55) 
 
G1               S             G2/M 
Serial 
passage 
38.6±1.0 45.6±1.7 15.6±2.8 89.6±6.0 5.2±1.0 5.52±0.3 
Starvation 
(120 hrs) 
89.8±2.5 0.83±0.6 9.3±1.9 97.7±2.2 0.06±.05 2.17±0.2 
Stimulation 
(6 hrs) 
81.4±2.0 4.2±0.3 14.2±1.8 96.1±5.1 1.0±0.5 3.1±0.1 
Stimulation 
(12 hrs) 
72.0±2.3 9.1±1.6 18.8±0.7 92.3±2.4 3.81±0.4 3.87±0.7 
Stimulation 
(24 hrs) 
31.7±3.2 60.5±2.1 7.6±1.8 87.6±4.9 7.0±0.7 5.35±0.4 
Culture 
condition 
HK1 Early passage (PD9) 
 
     G1               S             G2/M 
HK1 Late passage (PD60) 
 
    G1               S             G2/M 
Serial 
passage 
35.4±2.2 53.0±0.2 11.5±2.1 81.7±1 11.2±1.7 6.92±1.3 
Starvation 
(120 hrs) 
90.7±0.4 0.93±0.2 8.3±0.5 97.0±2.0 0.0±0.0 2.90±2.0 
Stimulation 
(6 hrs) 
86.2±1.5 3.51±0.5 9.92±0.9 95.3±1.4 1.0±0.7 3.68±0.7 
Stimulation 73.9±2.2 8.54±1.4 17.5±0.9 87.5±3.8 6.34±1.9 6.03±1.9 
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(12 hrs) 
Stimulation 
(24 hrs) 
30.4±4.0 61.6±6.4 7.6±2.1 78.5±4.6 13.0±2.7 8.36±1.9 
 
3.11 The enhanced expression of cell cycle inhibitors induced by telomere shortening is 
mitogen dependent.  
To monitor molecular markers of replicative senescence we followed gene expression 
levels of cell cycle inhibitors regulating the senescence pathway, namely p21 and p16 (67, 135, 
136) and expression levels of p19ARF, although its role in senescence is under debate (137, 
138). As established in previous studies an increased expression of p21 was detected in late 
passage cells (135, 136) (Figure 3.11.1E-L). In our study an upregulation of p21 was identified 
in the regenerating liver of G3 mTERC-/- mice compared to mTERC+/+ and G1 mTERC-/- mice 
(Figure 3.11.1A-D). Similarly an up-regulation of p16 was seen in late passage cells (136) 
(Figure 3.11.1E-L) but we did not observe an upregulation of p16 in the regenerating liver of 
G3 mTERC-/- mice (Figure 3.11.1A-D) in line with previously identified species differences in 
the regulation of p16 during senescence in mouse and human cells (13). We have not detected 
a significant up-regulation of p19ARF in either the in vitro or in vivo system (Figure 3.11.1).   
 
In accordance with our data on senescence morphology and SA-β-Gal-activity, the 
senescence-associated up-regulation of p21 in late passage cells and G3 mTERC-/- mice liver 
as well as the up-regulation of p16 in late passage cells were strongly induced when the cells 
were stimulated to enter the cell cycle by mitogen exposure (Figure 3.11.1A, D, E, F, H, I, J, 
L). Moreover, mitogen withdrawal reversed the up-regulation of these Cdk-inhibitors to a low, 
basal level when senescent late passage cells were transferred from serial passage in 10% FBS 
to serum starvation in 0.1% FBS (Figure 3.11.1 A, D, E, F, H, I, J, L).  
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Figure 3.11.1 Enhanced expression of cell cycle inhibitors associated with replicative 
senescence in response to telomere shortening is mitogen dependent. (A-C) Histograms on the 
level of mRNA expression of p21 (A), p16 (B), and P19ARF (C) in quiescent liver and 
regenerating liver (36hrs after PH) of mTERC+/+, G1 mTERC-/- and G3 mTERC-/- mice as 
revealed by RT-PCR. While p16 and p19ARF show no significant regulation, p21 was 
significantly over-expressed in G3 mTERC-/- mice only in response to partial hepatectomy 
(8±0.88 fold up-regulation compared to mTERC+/+ quiescent liver) but not in the quiescent 
organ. (D) Representative gel electrophoresis photograph showing the RT-PCR products of 
p21, p16, and p19ARF (after 22 cycles) and the house keeping gene RSP9 (after 35cycles): 
Lane 1. Quiescent mTERC+/+ liver, Lane 2. mTERC+/+ liver 30-36 hrs after PH, Lane 3. 
Quiescent G1 mTERC-/- liver, Lane 4. G1 mTERC-/- liver 30-36 hrs after PH, Lane 5. 
Quiescent G3 mTERC-/- liver, Lane 6. G3 mTERC-/- liver 30-36 hrs after PH, Lane 7. Non-
template control.  (E-G) Histograms showing p21 (E), p16 (F) and p19ARF (G) expression in 
early and late passage IMR90 cells and in late passage of hTERT expressing IMR90 cells. 
p21 and p16 were significantly up-regulated in late passage IMR90 cells but not in hTERT 
expressing cells. Note that serum starvation reversed the over-expression of p21 and p16, 
which re-appeared 12-24 hrs after serum re-stimulation. (H) Representative gel 
electrophorosis photograph showing the expression levels of p21, p16 and p19ARF (after 22 
cycles) and the house keeping gene β-actin (after 30 cycles) in IMR90 cells in the following 
loading order: 1-5: early passage IMR90 (PD30): 1. serial passage, 2. serum starvation for 120 
hrs, 3. serum stimulation (6 hrs), 4. serum stimulation (12 hrs), 5. serum stimulation (24 hrs). 
6-10: late passage IMR 90 (PD55): 6. serial passage, 7. serum starvation (120 hrs), 8. serum 
stimulation (6 hrs), 9. serum stimulation (12 hrs), 10. serum stimulation (24 hrs). 11-15: late 
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passage of hTERT expressing IMR90 cells (PD68): 11. serial passage, 12. serum starvation 
(120 hrs), 13. serum stimulation (6 hrs), 14. serum stimulation (12 hrs), 15. serum stimulation 
(24 hrs). 16. Non-template control. (I-K) Histograms showing p21 (I), p16 (J) and p19ARF (K) 
expression in early and late passage HK1 cells and in late passage of HK1 cells expressing 
hTERT. p21 and p16 were significantly up-regulated in late passage HK1 cells but not in 
hTERT expressing cells. Note that serum starvation partially reversed the over-expression of 
p16 and nearly completely rescued the over-expression of p21, which re-appeared 12-24 hrs 
after serum re-stimulation. (L) Representative gel electrophorosis photograph showing the 
expression levels of p21, p16 and p19ARF (after 22 cycles) and the house-keeping gene β-actin 
(after 30 cycles) in HK1 cells. The loading of PCR products for early (PD9), late (PD60) and 
hTERT immortalized (PD90) HK1 cells follow the same order as described for IMR90.  
 
In the liver system it has been reported that p21 is induced during cell cycle re-entry of 
quiescent hepatocytes following PH (139) indicating that it plays a role in regulating cell cycle 
re-entry during liver regeneration. However, the up-regulation of p21 in G3 mTERC-/- mice in 
response to PH greatly exceeded this physiological up-regulation of p21 in wildtype or G1 
mTERC-/- mice (Figure 3.11.1A & D).   
 
 
3.12 Inhibition of MEK/MAPK pathway partially abrogates the co-operation between 
mitogen stimulation and senescence signaling   
Treatment of cells with growth factors leads to activation of the mitogen activated 
protein kinases (MAPK) also called extracellular signal regulated kinases (ERK) by the 
MAPK/ERK-kinase (MEK). The Ras family members of onco-proteins activate this pathway 
in response to growth factor mediated dimerization of tyrosine-kinase receptors. Although 
necessary for normal cell proliferation, sustained over-stimulation of the Ras/MEK/MAPK-
pathway induces premature senescence.  Ras/MEK/MAPK-induced premature senescence is 
independent of telomere length and is characterized by the appearance of similar 
morphological and molecular markers as replicative senescence (84-86).   
To test whether the same mitogenic pathway also plays a role in revealing the 
phenotype of replicative senescence a highly specific pharmacological inhibitor of MEK 
(PD098059) was used to block this pathway (140-141).  When PD098059 was applied 1hr 
before and following serum stimulation of serum-starved late passage IMR90 cells the re-
appearance of senescence phenotypes (cell morphology and SA-β-Gal-activity, Figure 3.10.2) 
was partially prevented (Figure 3.12.1A-F). Similarly the up-regulation of p21 and p16 in late 
passage IMR90 in response to serum stimulation was significantly inhibited by addition of 
PD098059 (Figure 3.12.1G-I). Together, these data indicate that mitogen stimulation co-
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operates with senescence signaling through the activation of MEK/MAKP-pathway to reveal 
replicative senescence phenotypes.  
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Figure 3.12.1 (A, B) Histogram of the percentage of cells with senescent morphology or 
positive β-gal-staining in late passage IMR90 cells 120 hrs after serum starvation and 24 hrs 
after serum stimulation after addition of DMSO or the MEK-inhibitor PD098059  1 hr before 
stimulation. (C-F) Representative photographs showing the senescent morphology and β-gal 
activity in late passage IMR90 cells in response to serum stimulation for 24 hours after 
addition of DMSO (C, E) or the MEK-inhibitor PD098059 (D, F). (G) Fold difference of p21 
in late passage IMR90 cells 120 hrs after serum starvation and 24 hours after serum 
stimulation after addition of DMSO or the MEK-inhibitor PD098059. (H) Fold difference of 
p16 in late passage IMR90 cells 120 hrs after serum starvation and 24 hrs after serum 
stimulation after addition of DMSO  or the MEK-inhibitor PD098059. (I) Representative gel-
electrophoresis photograph of 10 µl of the RT-PCR products of p21 and p16 after 22 PCR-
cycles: 1. Late passage IMR90 cells under serum stimulation plus PD098059, 2. Late passage 
IMR90 cells under serum stimulation plus DMSO, 3. Non-template control. 
 
3.13.1 Hepatocyte-specific senescence in human liver cirrhosis 
To test whether the induction of cellular senescence in vivo in the mouse model can 
also apply to human liver, senescence associated-β-gal staining was conducted on human liver 
cirrhosis samples. In human liver cirrhosis, chronic hepatocyte destruction by viral hepatitis, 
AIH, PSC, PBC and concomitant hepatocyte regeneration accelerate telomere shortening in 
hepatocytes. If telomere shortening limits the regenerative capacity of hepatocytes signs of 
cellular senescence might be detectable in hepatocytes at the cirrhosis stage. To test this 
possibility, β-Gal staining was conducted on 49 of the cirrhosis samples and 15 of the control 
samples. In our study a strong correlation between senescence-associated-β-Gal activity and 
cirrhosis was detectable: 41 of 49 cirrhosis samples (84%) had β-Gal activity, whereas only 1 
of 15 control samples (7%) showed very weak β-Gal activity (Figure 3.13.1 A, P<0.0001). β-
Gal activity was detectable at a high frequency in all sub-groups of cirrhosis: in 90% of the 
AIH, 75% of the viral hepatitis, 85% of the PSC, 86% of the PBC, and 86% of the cirrhosis 
samples induced by alcoholism (Figure 3.13.1B ). Only hepatocytes stained positive for β-Gal 
whereas stellate cells in fibrotic septa did not stain positive for β-Gal in any samples tested 
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(Figure 3.13.1C). The β-Gal staining pattern of hepatocytes in cirrhosis is markedly 
pronounced at the edge of regenerative nodules as opposed to the center of the nodules (Figure 
3.13.1C). Since the regenerative nodules in the cirrhotic liver represent clonal expansion of 
regenerating hepatocytes, the cells at the edge of these nodules have undergone more cell 
divisions than cells in the centre, providing a possible explanation for the increase in 
senescence-associated β-Gal activity in these regions. Quantification of the percentage of β-
Gal-positive hepatocytes within cirrhosis samples showed that 32% of the cirrhosis samples 
have a weak β-gal activity (<5% of the hepatocytes), 32% have a moderate activity (5–15% of 
the hepatocytes), and 36% show strong activity (>15% of the hepatocytes). Together, our data 
show that there is a significant rate of hepatocellular senescence in cirrhosis limiting the 
regenerative capacity of the injured organ, thereby perturbing the balance of injury and 
regeneration, culminating in fibrotic scarring. 
 
 
 
Figure 3.13.1 Hepatocyte-specific senescence in cirrhosis. (A) 41 of 49 cirrhosis samples 
(84%) stain positive for senescence-associated β-Gal activity at pH 6, whereas only 1 of 15 
control samples shows very weak β-Gal activity (7%, P<0.0001). (B) High rates of 
senescence-associated ß-Gal activity are present in all subgroups of cirrhosis independent of 
its etiology: autoimmune hepatitis (AIH, 90%), alcoholism (C2, 86%), viral hepatitis (Hep, 
75%), primary biliary cirrhosis (PBC, 86%), primary sclerosing cholangitis (PSC, 85%). (C) 
Representative photograph of a noncirrhotic control sample showing no staining for 
senescence-associated β-Gal activity (left site, Bar: 200 µm), and a cirrhotic sample showing 
positive staining for senescence-associated β-Gal activity (right site, bar: 200 µm). Positive β-
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Gal staining of cirrhosis samples was restricted to hepatocytes and was not present in other 
cell types. Inlet: High magnification of an area showing hepatocyte-specific β-Gal staining 
(left site, arrow) at the edge to a fibrotic septum (right site); bar: 30 µm. β-Gal-positive 
hepatocytes (arrows) are predominantly located at the edge of regenerative nodules (RN), 
whereas stellate cells in fibrotic septa (FS) do not show β-Gal activity. 
 
3.14 Hepatocyte specific senescence correlates to fibrosis progression in cirrhosis 
          To test the hypothesis that limitation of hepatocyte regeneration by induction of 
senescence in hepatocytes triggers fibrotic scarring, we evaluated the correlation between the 
rate of senescent hepatocytes (β-Gal positive) and fibrosis. Cirrhosis samples were grouped 
into samples with mild fibrosis and samples with severe fibrosis according to the Ishak criteria 
(142). In line with our hypothesis, this analysis showed that samples with severe fibrosis have 
significantly higher rates of hepatocyte senescence than samples with milder fibrosis (Figure 
3.14.1). 
 
Figure 3.14.1 Correlation between β-Gal activity and fibrosis progression. Cirrhosis samples 
were grouped into samples with mild fibrosis and samples with severe fibrosis according to 
the Ishak criteria (19). There was a significant increase in the percentage of hepatocytes 
staining positive for β-gal activity in cirrhosis samples with severe fibrosis compared with 
cirrhosis samples with mild fibrosis. 
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4. Discussion 
 
Our current study demonstrates that telomere shortening at the cellular level affects 
organ regeneration in vivo by inhibiting a sub-population of cells with critically short 
telomeres from entering the cell cycle thereby limiting the pool of proliferating cells within an 
organ system. As a result there is an elevated regenerative pressure on the proliferating sub-
population of cells to compensate for impaired organ regeneration by additional rounds of cell 
divisions which in turn accelerates the rate of telomere shortening and the imbalance of 
proliferating and non-proliferating cells. Our results are further strengthened by previous 
studies in mTERC-/- mice showing that it is not the average telomere length, but the 
prevalence of critically short telomeres leads to regenerative disorders (100). The new concept 
derived from our study is that the prevalence of critically short telomeres at the cellular level 
determines the proliferative capacity of cells within an organ system. Thus, the regenerative 
capacity of organs and tissues depends on the size of the population of cells with sufficient 
telomere reserves required for cell proliferation.  
 
Which mechanism limits cell proliferation in the sub-population of cells with 
critically short telomeres? We show that mitogen signaling and apoptosis do not contribute to 
impaired liver regeneration in response to telomere shortening in our model system of PH.   It 
seems likely that the lack of telomere-directed apoptosis reflects the modest regenerative 
stress induced by PH unlike previous studies which showed that critical telomere shortening 
induces prominent hepatocyte apoptosis during clonal expansion of hepatocytes following 
acute liver failure - a setting of potent regenerative stress (98). The prevalence of β-
galactosidase positive cells and the coincidence of β-galactosidase activity with non-
proliferating cells indicate that the cells with critically short telomeres have reached the 
senescence stage. In line with this hypothesis gene expression profiling and RT-PCR analysis 
of regenerating liver at the onset of S-phase revealed an up-regulation of downstream targets 
of p53 - a pathway critical for inducing cellular senescence in response to telomere shortening 
(62, 66).  
 
At which stage of the cell cycle are the liver cells arrested? Previous studies in 
mTERC-/- mice have revealed that telomere shortening induces a biphasic cell cycle block in 
mouse embryonic fibroblasts (62) and impaired mitotic progression in regenerating liver (98). 
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In line with these studies, our current data on liver regeneration following PH show impaired 
cell cycle progression at 2 stages - at pre-S-phase and G2/M.: impaired S-phase entry in G3 
mTERC-/- mice was independent of the DNA content of the cells demonstrating that G1/S 
progression was impaired, and the accumulation of cells with higher DNA ploidy in G3 
mTERC-/- mice during the time course of liver regeneration indicated that G2/M progression 
was impaired. We hypothesize that if telomeres are dysfunctional in resting cells, cell cycle 
re-entry is inhibited at the G1/S transition. In addition, some cells will acquire dysfunctional 
telomeres during S-phase due to further telomere shortening during DNA replication and will 
consequently be withdrawn from the cell cycle at the G2/M stage.  
 
 
 
Figure 4.1 Model on the consequences of telomere shortening at the cellular level on cell 
cycle progression. Telomere shortening is heterogeneous with in the cells of an organ system. 
Cells with higher level of telomere dysfunction were inhibited from entering the cell cycle at 
G1/S transition where as other cells with some telomere dysfunction enter the S phase and the 
consequent loss of  few more telomere repeats during S phase lead to telomere dysfunction 
and consequently these cells are inhibited at G2/M checkpoint of the cell cycle. So the level of 
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telomere dysfunction determines the proliferative fate of the cell and the activation of cell 
cycle checkpoints.  
 
Our study supports a model that inhibition of cell cycle entry in a sub-population of 
cells with critically short telomeres results in delayed organ regeneration by requiring an 
additional round of replication by cells with sufficient telomere reserves. According to this 
model regenerative defects are determined by the size of the proliferating population of cells 
within an organ system necessary to maintain organ function and homeostasis. It seems likely 
that the differences in telomere length between individual cells within an organ reflect the 
replicative history of cells during organogenesis and postnatal life. In addition, other factors 
that possibly affect telomere length might be differences in metabolic rates and intracellular 
load of radical oxygen species. The percentage of liver cells inhibited from cell cycle re-entry 
in G3 mTERC-/- mice in our study was approximately 15%, most of them (~11%) in turn 
showed β-galactosidase activity.  
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Figure 4.2 Model of impaired regeneration of organs induced by telomere shortening 
at cellular level. Within a tissue or organ system heterogeneous telomere shortening inhibits a 
growing sub-population of cells from entering the cell cycle and the pool of proliferating cells 
will constantly decrease. This reduced pool of cells with sufficient telomere reserves has to 
undergo additional cell divisions to accomplish organ/tissue regeneration. This mechanism 
will lead to acceleration of telomere shortening and will further disturb the imbalance of 
proliferating and non-proliferating cells. 
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Similarly our present study shows that the phenotypes and signaling pathways of 
replicative senescence induced by telomere shortening in both in vivo and in vitro are revealed 
by mitogen stimulation. The senescent signaling become amplified to a higher level in cells 
that are stimulated to divide where as operate at a low, basal level in the absence of a growth 
response.  We show that the morphological phenotypes as well as the molecular markers of 
cellular senescence are dramatically diminished in mitogen-deprived cells and organs despite 
the prevalence of critically short telomeres. The senescence markers (re-) appear in response to 
mitogen induced proliferative response both in vitro and in vivo indicating that responses to 
telomere dysfunction are still intact.  Activation of the replicative senescence program in 
response to mitogenic stimuli signals in part through the MEK/MAPK-pathway inducing 
premature senescence in response to sustained over-stimulation of this pathway (84-86). Our 
data indicate that both senescence pathways (premature and replicative senescence) are linked 
to each other. We suggest the hypothesis that telomere shortening lowers the threshold at 
which MEK/MAPK-signaling induces growth arrest and senescence instead of cell 
proliferation. In line with this hypothesis previous studies have shown that premature 
senescence and replicative senescence are indistinguishable in terms of morphological and 
molecular markers (87). Recently it has been shown that the stress induced MAPK 38 - is 
over-expressed in both, replicative and premature senescence (89) indicating that there could 
be a cross-talk between mitogen stimulation and the stress induced MAPK 38 possibly 
functioning at a lower threshold in cells with shortened telomeres.  
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Figure 4.3 Model showing the co-operation between mitogenic stimuli and telomere 
shortening to activate p21 signaling pathway to prevent the cells to enter cell cycle. 
 
An explanation for the mitogen-dependence of replicative senescence is that a low 
level of cell cycle inhibitors is sufficient to counteract the actions of positive growth regulatory 
elements which are either absent or present at very low levels in growth deprived conditions 
(67). Quiescent young as well as senescent HDFs (Human diploid fibroblasts) express low 
levels of cyclin D1 and cyclin E and upon serum stimulation both their expression and their 
associated kinase activities increase during the mid and late G1 phases respectively in young 
HDFs which leads to pRb phosphorylation (67, 78, 79). In contrast to the young HDFs, in 
senescent HDFs even though there is abundant cyclin D-Cdk4/6 and cyclin E-Cdk2  complexs 
they lack cyclin E and cyclin D associated kinase activities which is due to increased inhibitory 
binding of p21 to these complexes rather than inhibitory phosphorylation of  kinase activity 
(67, 79).  
 
In our study the enhanced expression of p21 in response to serum stimulation reflects 
the fact that a higher level of p21 is essential to inhibit the growth stimulatory effects of cyclin 
D-Cdk4/6 and cyclin E-Cdk2 complexs. The moderate up-regulation of Cdk-inhibitors, which 
is the physiological response to mitogenic stimuli (139), gives a plausible explanation that 
there is a fine balance between expression levels of positive growth regulators and inhibitors 
for controlled proliferation of cells and the shift of this balance to either side depends on the 
physiological as well as molecular status of the cell.  
 
Our study shows that in cells with shortened telomeres the up-regulation of p21 and 
p16 in response to mitogen stimulation greatly exceeded the normal physiological levels 
inorder to prevent the cells from entering the cell cycle. In contrast to the almost complete 
diminution of p21 over-expression in human senescent cells by mitogen withdrawal, the 
diminution of p16 over-expression was partial and in-complete (Figure 3.11.1) indicating that 
the secondary upregulation and accumulation of p16 at the senescent stage is partially 
independent of mitogenic stimuli or that its decline is delayed.  The disappearance of 
morphological characteristics of senescent cells is in correlation with diminution of expression 
levels of p21 and p16 in response to serum deprivation indicates that the expression levels of 
these cell cycle regulators determine not only the proliferative fate but also the morphological 
features of the cells. This explanation is in accord with previous reports that the induced 
expression of either p21 or p16 alone is sufficient to induce senescence which show all the 
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morphological markers of senescence including flattened morphology and SA-β-gal activity 
(143-144) and inhibition of p21 and p16 leads to normal cell cycle progression and extension 
of life span with no signs of senescence (145, 146). In our current study the disappearance and 
reappearance of morphological features of senescence (flattened cells, SA-β-gal activity) in 
response to serum starvation and stimulation are in correlation with the expression levels of 
p21 and p16. It appears that the expression levels of these genes can determine the 
morphological characteristics of cells through either activation or inhibition of a cascade of 
some unknown signal transduction pathways. 
 
The classical model of replicative senescence is that critically short telomeres loose 
their capping-function at the chromosomal ends resulting in activation of a DNA-damage 
response culminating in cellular senescence (13-16, 66). Our findings that the morphological 
and molecular markers of senescence are revealed by mitogen stimulation independent of 
further telomere shortening in the subsequent cell division suggest that the "un-capped" 
chromosomal ends might not generate a DNA-damage signal as long as the cells are in the 
quiescent stage. Possible explanations are that the chromosomal ends might be protected by 
dense packing of the chromatin in G0 cells as compared to cells entering the cell cycle, or those 
genes involved in DNA-damage recognition and signaling are actively suppressed in quiescent 
cells. The results of our study will impact on future analysis of the senescence-pathway and 
might help to identify the initial responses to telomere shortening leading to cell cycle arrest 
and senescence. Regarding the role of replicative senescence in vivo our findings indicate the 
need to monitor cell cycle activity in order to analyze the prevalence and consequences of 
senescence in different organs and tissues often containing large fraction of cells in the G0-
stage of the cell cycle.    
 
Does the telomere hypothesis of induction of cellular senescence and impaired organ 
regeneration in mouse models apply to humans? To date there is an accumulation of 
correlative data indicating that telomere shortening might impact on the regenerative capacity 
of human tissues during aging and chronic diseases. In addition, mutation of the essential 
RNA component of human telomerase has been implicated in premature aging, bone marrow 
failure, and liver cirrhosis among other phenotypes in patients with dyskeratosis congenita 
(147). Since it is not possible to study the consequences of telomere shortening in a 
regenerative model in humans, we explored the existance of cellular senescence in human 
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cirrhosis samples where continuous destruction and concomitant regeneration of liver cells 
occurs in response to a broad variety of liver diseases.  
 
Our study revealed the existance of cellular senescence in human cirrhosis and the 
prevalence of senescent hepatocytes ranges from 2-15% in the vast majority of cases 
indicating that cellular senescence impairs regular organ regeneration in chronic liver disease 
in humans. Moreover, cellular senescence at the cirrhosis stage correlates with fibrosis 
progression. The determination of the rates of cellular senescence and the identification of 
new markers of senescence could be useful to test the relevance of senescence in limiting the 
regenerative capacity in different human tissues and organs during aging and chronic disease. 
 
Our data support the telomere hypothesis of human cirrhosis, suggesting that chronic 
hepatocyte damage and concomitant hepatocyte regeneration accelerate telomere shortening 
in hepatocytes. When hepatocytes reach the senescent stage, liver regeneration decreases but 
the chronic liver damage continues. At this stage of disease, other cell types, like hepatic 
stellate cells, which usually do not participate in the regenerative process, become activated 
and form fibrotic scar tissue in areas of hepatocyte loss.  
 
It will be important to identify the signals inducing hepatocellular senescence once 
telomeres have reached a critically short length. The tumor suppressor p53 has been identified 
as a downstream target of short dysfunctional telomeres in mouse and human cells (13) . 
Inhibition of p53 rescues the adverse effects of telomere dysfunction (62). The data on 
accumulation of p21 in cirrhotic samples indicate this pathway might also be activated at the 
cirrhosis stage (115). However, the mechanism of p53 activation and the role of other 
pathways in response to critical telomere shortening remain to be identified. 
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Figure 4.4 Model of hepatocyte specific senescence and its correlation with cirrhosis 
formation and fibrosis progression. This model delineates that chronic liver diseases 
constitutively damage hepatocytes thus accelerating the rate of hepatocyte turnover, which in 
turn leads to hepatocyte telomere shortening and senescence. According to this model the 
formation of fibrotic scar is triggered by loss of hepatocyte regeneration and persistent organ 
damage which then leads to the activation of stellate cells with longer telomeres to replace 
organ mass by scar tissue compromising normal organ architecture and function.  
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